

=> d his ful

(FILE 'HOME' ENTERED AT 14:03:12 ON 10 NOV 2005)

FILE 'REGISTRY' ENTERED AT 14:03:22 ON 10 NOV 2005

L1 2 SEA ABB=ON (DIHYDROQUERCETIN OR ARALOSIDE)/CN

FILE 'HCAPLUS' ENTERED AT 14:04:08 ON 10 NOV 2005

E RAMAZANOV ARTHUR/AU

L2 1 SEA ABB=ON "RAMAZANOV ARTHUR"/AU

E RAMAZANOV ZAKIR/AU

L3 10 SEA ABB=ON "RAMAZANOV ZAKIR"/AU

L4 1 SEA ABB=ON L2 AND L3

L5 ANALYZE L4 1-1 CT : 17 TERMS

FILE 'HCAPLUS' ENTERED AT 14:08:35 ON 10 NOV 2005

E OBESITY/CT

E OBESITY+ALL/CT

L6 274064 SEA ABB=ON OBESITY+ALL/CT

E BODY WEIGHT REDUCTION+ALL/CT

E E2+ALL

L7 51039 SEA ABB=ON "BODY WEIGHT"+ALL/CT

E BODY FAT MASS+ALL

E BODY FAT MASS+ALL/CT

L8 39357 SEA ABB=ON "BODY FAT"+ALL/CT

L9 280812 SEA ABB=ON L6 OR L7 OR L8

L10 23 SEA ABB=ON L9 AND (L1 OR ?DIHYDROQUERCETIN? OR ?ARALOSIDE?)

L11 14 SEA ABB=ON L10 AND (PRD<20030106 OR PD<20030106)

FILE 'BIOSIS' ENTERED AT 14:12:12 ON 10 NOV 2005

E OBESITY+ALL/CT

E E3+ALL

L12 25261 SEA ABB=ON OBESITY/CT

E BODY WEIGHT REDUCTION/CT

L13 15 SEA ABB=ON ("BODY WEIGHT REDUCTION"+ALL/CT OR "BODY WEIGHT
REGULATING COMPOUNDS"+ALL/CT OR "BODY WEIGHT REGULATION"+ALL/CT
OR "BODY WEIGHT REGULATION EFFECTS"+ALL/CT OR "BODY WEIGHT
REGULATION ROLE"+ALL/CT OR "BODY WEIGHT REGULATOR"+ALL/CT)
E BODY FAT MASS REDUCTION/CT

L14 3 SEA ABB=ON "BODY FAT MASS"+ALL/CT

L15 90 SEA ABB=ON (?BODY?(W)FAT?(W)?MASS?)(3A)(?REDUC? OR ?REGULAT?
OR ?CONTROL?)

L16 7849 SEA ABB=ON (?BODY?(W)?WEIGHT?)(3A)(?REDUC? OR ?REGULAT? OR
?CONTROL?)

L17 32342 SEA ABB=ON L12 OR L13 OR L14 OR L15 OR L16

L18 0 SEA ABB=ON L17 AND (L1 OR ?DIHYDROQUERCETIN? OR ?ARALOSIDE?)

FILE 'MEDLINE' ENTERED AT 14:17:13 ON 10 NOV 2005

E OBESITY/CT

L19 1467389 SEA ABB=ON OBESITY+ALL/CT

E (?BODY?(W)?WEIGHT?)(3A)(?REDUC? OR ?REGULAT? OR ?CONTROL?)

E BODY WEIGHT REDUCTION+ALL

E BODY WEIGHT REDUCTION+ALL/CT

L20 29428 SEA ABB=ON "BODY WEIGHT: DE, DRUG EFFECTS"/CT

E BODY FAT MASS+ALL/CT

L21 100 SEA ABB=ON (?BODY?(W)FAT?(W)?MASS?)(3A)(?REDUC? OR ?REGULAT?
OR ?CONTROL?)

L22 1467429 SEA ABB=ON L19 OR L20 OR L21

L23 1 SEA ABB=ON L22 AND (L1 OR ?DIHYDROQUERCETIN? OR ?ARALOSIDE?)

*representative
structures
included with
search printout*

FILE 'EMBASE' ENTERED AT 14:20:54 ON 10 NOV 2005

E OBESITY+ALL/CT
L24 67898 SEA ABB=ON OBESITY+ALL/CT
E BODY WEIGHT REDUCTION+ALL/CT
L25 24193 SEA ABB=ON "WEIGHT REDUCTION"/CT
E BODY FAT MASS+ALL/CT
L26 5 SEA ABB=ON "BODY FAT MASS"+ALL/CT
L27 191296 SEA ABB=ON "BODY FAT"+ALL/CT
L28 191296 SEA ABB=ON L26 OR L27
L29 229178 SEA ABB=ON L24 OR L25 OR L28
L30 0 SEA ABB=ON L29 AND (L1 OR ?DIHYDROQUERCETIN? OR ?ARALOSIDE?)

FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 14:23:00 ON 10 NOV 2005

L31 3 SEA ABB=ON L10
L32 3 DUP REMOV L31 (0 DUPLICATES REMOVED)

FILE 'HCAPLUS' ENTERED AT 14:23:45 ON 10 NOV 2005

L33 115470 SEA ABB=ON (?OBES? OR ?BODY?)(W)(FAT? OR ?WEIGHT?)
L34 2 SEA ABB=ON L33 AND (L1 OR ?DIHYDROQUERCETIN? OR ?ARALOSIDE?)
L35 0 SEA ABB=ON L34 AND (PRD<20030106 OR PD<20030106)
L36 2 SEA ABB=ON L34 AND (L1 OR ?DIHYDROQUERCETIN? OR ?ARALOSIDE?)

FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 14:25:54 ON 10 NOV 2005

L37 2 SEA ABB=ON L36
L38 2 DUP REMOV L37 (0 DUPLICATES REMOVED)

FILE 'USPATFULL' ENTERED AT 14:26:35 ON 10 NOV 2005

L39 1 SEA ABB=ON L10 AND (PRD<20030106 OR PD<20030106)
L40 47 SEA ABB=ON L34 AND (L1 OR ?DIHYDROQUERCETIN? OR ?ARALOSIDE?)
L41 47 SEA ABB=ON L39 OR L40
L42 42 SEA ABB=ON L41 AND ?MAMMAL?
L43 42 SEA ABB=ON L42 AND ?METHOD? *42 cit's from USpatfull*

FILE 'HCAPLUS' ENTERED AT 14:28:22 ON 10 NOV 2005

L44 16 SEA ABB=ON L11 OR L36 *16 cit's from CAPLUS*

FILE 'MEDLINE, BIOSIS, EMBASE, JAPIO, JICST-EPLUS' ENTERED AT 14:29:45 ON 10 NOV 2005

L45 4 SEA ABB=ON L23 OR L32 OR L38
L46 4 DUP REMOV L45 (0 DUPLICATES REMOVED) *4 cit's from above d.b.'s*

FILE HOME

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 NOV 2005 HIGHEST RN 866995-49-5
DICTIONARY FILE UPDATES: 8 NOV 2005 HIGHEST RN 866995-49-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 10 Nov 2005 VOL 143 ISS 20
FILE LAST UPDATED: 9 Nov 2005 (20051109/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE BIOSIS

FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 9 November 2005 (20051109/ED)

FILE RELOADED: 19 October 2003.

FILE MEDLINE

FILE LAST UPDATED: 9 NOV 2005 (20051109/UP). FILE COVERS 1950 TO DATE.

On December 19, 2004, the 2005 MeSH terms were loaded.

The MEDLINE reload for 2005 is now available. For details enter HELP RLOAD at an arrow prompt (=>). See also:

<http://www.nlm.nih.gov/mesh/>
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html

OLDMEDLINE now back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2005 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE EMBASE

FILE COVERS 1974 TO 3 Nov 2005 (20051103/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE JAPIO

FILE LAST UPDATED: 4 NOV 2005 <20051104/UP>

FILE COVERS APR 1973 TO JUNE 30, 2005

<<< GRAPHIC IMAGES AVAILABLE >>>

FILE JICST-EPLUS

FILE COVERS 1985 TO 8 NOV 2005 (20051108/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 10 Nov 2005 (20051110/PD)

FILE LAST UPDATED: 10 Nov 2005 (20051110/ED)

HIGHEST GRANTED PATENT NUMBER: US6964061

HIGHEST APPLICATION PUBLICATION NUMBER: US2005251889

CA INDEXING IS CURRENT THROUGH 10 Nov 2005 (20051110/UPCA)

ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 10 Nov 2005 (20051110/PD)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2005

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2005

>>> USPAT2 is now available. USPATFULL contains full text of the <<<
>>> original, i.e., the earliest published granted patents or <<<
>>> applications. USPAT2 contains full text of the latest US <<<
>>> publications, starting in 2001, for the inventions covered in <<<
>>> USPATFULL. A USPATFULL record contains not only the original <<<
>>> published document but also a list of any subsequent <<<
>>> publications. The publication number, patent kind code, and <<<
>>> publication date for all the US publications for an invention <<<
>>> are displayed in the PI (Patent Information) field of USPATFULL <<<
>>> records and may be searched in standard search fields, e.g., /PN, <<<
>>> /PK, etc. <<<

>>> USPATFULL and USPAT2 can be accessed and searched together <<<
>>> through the new cluster USPATALL. Type FILE USPATALL to <<<
>>> enter this cluster. <<<
>>> <<<
>>> Use USPATALL when searching terms such as patent assignees, <<<
>>> classifications, or claims, that may potentially change from <<<
>>> the earliest to the latest publication. <<<

This file contains CAS Registry Numbers for easy and accurate substance identification.

Representative Structures

Spivack 10/660,256

10/11/2005

=> d 1-2

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN

RN 39384-09-3 REGISTRY

ED Entered STN: 16 Nov 1984

CN **Araloside (9CI)** (CA INDEX NAME)

OTHER NAMES:

CN Araloside ABC

MF Unspecified

CI MAN

LC STN Files: AGRICOLA, BIOSIS, CA, CAPLUS, IPA, NAPRALERT, TOXCENTER,
USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
14 REFERENCES IN FILE CA (1907 TO DATE)
5 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
14 REFERENCES IN FILE CAPLUS (1907 TO DATE)

ED Entered STN: 16 Nov 1984

L1 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2005 ACS on STN

RN 480-18-2 REGISTRY

ED Entered STN: 16 Nov 1984

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R-trans)-

CN Flavanone, 3,3',4',5,7-pentahydroxy- (8CI)

OTHER NAMES:

CN (+)-Dihydroquercetin

CN (+)-Taxifolin

CN (2R,3R)-Dihydroquercetin

CN 2,3-Dihydroquercetin

CN 3,5,7,3',4'-Pentahydroxyflavanone

CN **Dihydroquercetin**

CN Diquertin

CN Distylin

CN Taxifolin

CN Taxifoliol

FS STEREOSEARCH


DR 24198-96-7, 17654-26-1, 20254-28-8, 98006-93-0, 5117-01-1, 5323-70-6,
28929-10-4

MF C15 H12 O7

CI COM

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS,
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CHEMCATS, CHEMLIST,
CSCHEM, DDFU, DRUGU, EMBASE, HODOC*, IPA, MEDLINE, NAPRALERT, PIRA,
PROMT, RTECS*, SPECINFO, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: EINECS**, NDSL**, TSCA**
(**Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1312 REFERENCES IN FILE CA (1907 TO DATE)
39 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1316 REFERENCES IN FILE CAPLUS (1907 TO DATE)
10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

ED Entered STN: 16 Nov 1984

=> d

L47 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN

RN 7518-22-1 REGISTRY

ED Entered STN: 16 Nov 1984

CN β -D-Glucopyranosiduronic acid, (3 β)-28-(β -D-glucopyranosyloxy)-28-oxoolean-12-en-3-yl 4-O- α -L-arabinofuranosyl- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN **Araloside A (7CI)**

CN Chikusetsusaponin IV (8CI)

CN Oleanane, β -D-glucopyranosiduronic acid deriv.

OTHER NAMES:

CN Chikusetsusaponin 4

CN Oleanoside E

FS STEREOSEARCH

DR 51268-81-6, 65722-08-9


MF C47 H74 O18

LC STN Files: AGRICOLA, ANABSTR, BEILSTEIN*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CAOLD, CAPLUS, DDFU, DRUGU, EMBASE, IPA, MEDLINE, NAPRALERT, RTECS*, TOXCENTER


(*File contains numerically searchable property data)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

102 REFERENCES IN FILE CA (1907 TO DATE)

102 REFERENCES IN FILE CAPLUS (1907 TO DATE)

10 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

ED Entered STN: 16 Nov 1984

=> d ibib abs ind l4 1-1

L4 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:612490 HCAPLUS
 DOCUMENT NUMBER: 141:134105
 TITLE: Novel composition for the treatment of obesity and effective fat loss promotion
 INVENTOR(S): **Ramazanov, Arthur; Ramazanov, Zakir**
 PATENT ASSIGNEE(S): National Bioscience Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004147460	A1	20040729	US 2003-660256	20030911
PRIORITY APPLN. INFO.:			US 2003-438113P	P 20030106

AB The present invention encompasses pharmaceutical compns. for the treatment of obesity. These compns. comprise dihydroquercetins (dihydroquercetin 3-rhamnoside and its aglycon dihydroquercetin) and the triterpene saponins known as aralosides or elatosides. The compns. of the present invention effectively promote total weight loss and body fat mass loss. Therefore, the present invention is also directed to methods for treating obesity, reducing total weight, and reducing body fat mass by administering the compns. of the invention. The invention also embraces methods for disrupting the perilipin shell of lipid droplets and stimulating the activity of hormone-sensitive lipase. A dried powdered extract comprising

15-25 % by weight of dihydroquercetins and 15-25 % by weight of aralosides (from leaves of Engelhardtia chrysolepis and Aralia mandshurica bark and root, resp.) was effective in the treatment of obesity.

IC ICM A61K031-7048
 ICS A61K031-704; A61K031-353

INCL 514025000; 514027000; 514456000

CC 1-10 (Pharmacology)
 Section cross-reference(s): 11, 63

ST obesity treatment fat loss promotion dihydroquercetin araloside compd; dihydroquercetin araloside compd antiobesity agent; disruption perilipin shell lipid droplet dihydroquercetin araloside compd; hormone sensitive lipase stimulation dihydroquercetin araloside compd

IT Aralia elata
 (aralosides extraction from bark and root of; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Bark
 Root
 (aralosides extraction from, or Aralia mandshurica; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Glycerides, biological studies
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (blood, dried powdered extract containing dihydroquercetins and aralosides reduction of; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Drug delivery systems

(capsules; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Adipose tissue
 Antiobesity agents
 Blood
 Drug delivery systems
 Human
 Mammalia
 Obesity
 (dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Engelhardtia chrysolepis
 (dihydroquercetins extraction from leaves of; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Leaf
 (dihydroquercetins extraction from, of Engelhardtia chrysolepis; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Fatty acids, biological studies
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (dried powdered extract containing dihydroquercetins and aralosides induction of increased levels in plasma of; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Organelle
 (lipid droplet, disruption of perilipin shell of, in obesity treatment; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Body weight
 (loss; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT Proteins
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)
 (perilipin, disruption of shell of, of lipid droplets, in obesity treatment; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT 480-18-2P, Dihydroquercetin 29838-67-3P
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT 480-18-2D, Dihydroquercetin, compds. 39384-09-3D, Araloside, compds.
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT 64-17-5, Ethanol, uses 7732-18-5, Water, uses
 RL: NUU (Other use, unclassified); USES (Uses)
 (plant extraction with solvent containing; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

IT 9001-62-1
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (stimulation of, in obesity treatment; dihydroquercetins and aralosides in novel compns. for treatment of obesity and effective fat loss promotion)

Spivack 10/660,256

10/11/2005

promotion)

=> d que stat 144

L1 2 SEA FILE=REGISTRY ABB=ON (DIHYDROQUERCETIN OR ARALOSIDE)/CN
L6 274064 SEA FILE=HCAPLUS ABB=ON OBESITY+ALL/CT
L7 51039 SEA FILE=HCAPLUS ABB=ON "BODY WEIGHT"+ALL/CT
L8 39357 SEA FILE=HCAPLUS ABB=ON "BODY FAT"+ALL/CT
L9 280812 SEA FILE=HCAPLUS ABB=ON L6 OR L7 OR L8
L10 23 SEA FILE=HCAPLUS ABB=ON L9 AND (L1 OR ?DIHYDROQUERCETIN? OR
?ARALOSIDE?)
L11 14 SEA FILE=HCAPLUS ABB=ON L10 AND (PRD<20030106 OR PD<20030106)
L33 115470 SEA FILE=HCAPLUS ABB=ON (?OBES? OR ?BODY?) (W) (FAT? OR
?WEIGHT?)
L34 2 SEA FILE=HCAPLUS ABB=ON L33 AND (L1 OR ?DIHYDROQUERCETIN? OR
?ARALOSIDE?)
L36 2 SEA FILE=HCAPLUS ABB=ON L34 AND (L1 OR ?DIHYDROQUERCETIN? OR
?ARALOSIDE?)
L44 16 SEA FILE=HCAPLUS ABB=ON L11 OR L36

=> d ibib abs 144 1-16

L44 ANSWER 1 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:1036932 HCAPLUS
DOCUMENT NUMBER: 141:420489
TITLE: Use of plant extract with flavonoids rich in
proanthocyanidins for the treatment of migraine
INVENTOR(S): Stenswick, Larry Ellsworth; Chayasirisobhon, Sirichai
PATENT ASSIGNEE(S): Enzo Nutraceuticals Limited, N. Z.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103411	A1	20041202	WO 2004-NZ95	20040521
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: NZ 2003-526098 A 20030523

AB The invention relates to uses and methods of treating migraine with a plant extract that includes a therapeutically ED of a mixture of flavonoids rich in proanthocyanidins. Methods and uses are described to substantially prevent migraine from occurring, reduce the frequency of migraine, or reduce the severity of migraine symptoms.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 2 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2004:905378 HCAPLUS
DOCUMENT NUMBER: 141:370582
TITLE: Dietary supplement containing chelators for removing

heavy metals
 INVENTOR(S): Coleman, Henry D.; Sudol, R. Neil; Sapone, William J.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 12 pp., Cont.-in-part of U.S.
 Ser. No. 123,576.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004213829	A1	20041028	US 2004-852391	20040524 <--
US 2003194453	A1	20031016	US 2002-123576	20020415
PRIORITY APPLN. INFO.:			US 2002-123576	A2 20020415 <--

AB A dietary supplement, preferably formulated with a confectionery base, removes or prevents the bio-accumulation of heavy metals in the body. The supplement has one or more natural chelators, or precursors therefore, with at least one chelator capable of crossing the blood brain barrier to capture a heavy metal ion from a site in the central nervous system. The chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. Preferably, one or more secondary chelators bind any of the heavy metal released from the primary chelator and hold it for removal via an excretion pathway. In one embodiment, the supplement includes glutathione or metallothioneine to assist in moving the chelated heavy metal out into the excretion pathway. Using the dietary supplement limits the accumulation of heavy metals in the body, promotes removal of heavy metals previously accumulated in the body and thereby alleviates the symptoms and conditions associated with heavy metal toxicity. Compns. were given containing chelators such as α -lipoic acid or quercetin.

L44 ANSWER 3 OF 16 HCAPLUS COPYRIGHT 2005 ACS, on STN

ACCESSION NUMBER: 2004:612490 HCAPLUS
 DOCUMENT NUMBER: 141:134105
 TITLE: Novel composition for the treatment of obesity and effective fat loss promotion
 INVENTOR(S): Ramazanov, Arthur; Ramazanov, Zakir
 PATENT ASSIGNEE(S): National Bioscience Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 14 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004147460	A1	20040729	US 2003-660256	20030911
PRIORITY APPLN. INFO.:			US 2003-438113P	P 20030106


AB The present invention encompasses pharmaceutical compns. for the treatment of obesity. These compns. comprise **dihydroquercetins** (**dihydroquercetin** 3-rhamnoside and its aglycon **dihydroquercetin**) and the triterpene saponins known as **aralosides** or **elatosides**. The compns. of the present invention effectively promote total weight loss and **body fat** mass loss. Therefore, the present invention is also directed to methods for treating obesity, reducing total weight, and reducing **body fat** mass by administering the compns. of the invention. The invention also embraces methods for disrupting the perilipin shell of

lipid droplets and stimulating the activity of hormone-sensitive lipase. A dried powdered extract comprising 15-25 % by weight of **dihydroquercetins** and 15-25 % by weight of **aralosides** (from leaves of Engelhardtia chrysolepis and Aralia mandshurica bark and root, resp.) was effective in the treatment of obesity.

L44 ANSWER 4 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:319452 HCAPLUS
DOCUMENT NUMBER: 138:314630
TITLE: Orthomolecular sulfo-adenosylmethionine derivatives with antioxidant properties
INVENTOR(S): Wilburn, Michael D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 17 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078231	A1	20030424	US 2001-886612	20010622 <--
PRIORITY APPLN. INFO.:			US 2001-886612	20010622 <--
OTHER SOURCE(S):	MARPAT	138:314630		
GI				



AB Disclosed are orthomol. sulfo-adenosylmethionine derivative compds., compns., and their uses for effecting a biol. activity in an animal, such as neurochem. activity; liver biol. activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compds. of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compds. of the present invention are I (R1 = H, C1-C10 alkyl, C2-C10 alkenyl or alkynyl, -C(O)R2; R2 = C1-C10 alkyl, C2-C10 alkenyl or alkynyl; Q = -C(NH3)C(O)AX, -C(COOH)NHX; A = O, N; X = a defined reaction product) or pharmaceutically acceptable salt, ester or solvate thereof. α -(S-adenosylmethionine)-O-tocopherol was prepared from N-Acetyl-S-benzyl-L-homocysteine, α -tocopherol, and 5'-O-p-Tolylsulfonyladenine.

L44 ANSWER 5 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:175578 HCAPLUS
DOCUMENT NUMBER: 139:301956
TITLE: Effect of metal ions on biological activity of natural flavonoids
AUTHOR(S): Potapovich, A. I.; Vladykovskaya, E. N.; Kostyuk, V. A.
CORPORATE SOURCE: Beloruss. Gos. Univ., Belarus
SOURCE: Doklady Natsional'noi Akademii Nauk Belarusi (2002), 46(6), 60-63
CODEN: DNABFW; ISSN: 1561-8323
PUBLISHER: Belaruskaya Navuka
DOCUMENT TYPE: Journal
LANGUAGE: Russian

AB Influence of metal ions (Fe²⁺, Fe³⁺, Cu²⁺) on antiradical properties of rutin, **dihydroquercetin**, ECG, EGCG, and cytoprotective action of flavonoid metal complexes against asbestos-induced oxidative cell injury was studied. It was found that the metals increase the capacity of rutin and **dihydroquercetin** to project peritoneal macrophages and neutrophils against injury caused by chrysotile asbestos fibers. This effect is due to the formation of the flavonoid metal complexes with high antiradical activity against superoxide. The results also demonstrate that the flavonoid metal complexes were absorbed by chrysotile fibers much better than uncomplexed compds., and therefore, flavonoid metal complexes are better protectors against asbestos-induced hemolysis. The flavonoid metal complexes may result in better clin. therapies for diseases mediated by ROS.

L44 ANSWER 6 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:527738 HCAPLUS
DOCUMENT NUMBER: 137:305884
TITLE: Prooxidant activity and cellular effects of the phenoxyl radicals of dietary flavonoids and other polyphenolics
AUTHOR(S): Galati, Giuseppe; Sabzevari, Omid; Wilson, John X.; O'Brien, Peter J.
CORPORATE SOURCE: Faculty of Pharmacy, Department of Pharmacology, University of Toronto, Toronto, ON, M5S 2S2, Can.
SOURCE: Toxicology (2002), 177(1), 91-104
CODEN: TXCYAC; ISSN: 0300-483X
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Dietary polyphenolics in fruits, vegetables, wines, spices and herbal medicines have beneficial antioxidant, anti-inflammatory and anticancer effects. However, the authors have observed that dietary polyphenolics with phenol rings were metabolized by peroxidase to form prooxidant phenoxyl radicals which, in some cases were sufficiently reactive to cooxidize GSH or NADH accompanied by extensive oxygen uptake and reactive oxygen species formation. The order of catalytic effectiveness found for oxygen activation when polyphenolics were metabolized by peroxidase in the presence of GSH was phloretin>phloridzin > 4,2'-dihydroxy chalcone > p-coumaric acid > naringenin > apigenin > curcumin > resveratrol > isoliquiritigenin > capsaicin > kaempferol. Ascorbate was also cooxidized by the phenoxyl radicals but without oxygen activation. Polyphenolics with catechol rings also cooxidized ascorbate, likely mediated by semiquinone radicals. The order of catalytic effectiveness found for ascorbate cooxidn. was fisetin luteolin, quercetin, > eriodictyol, caffeic acid, nordihydroguaiaretic acid>catechin>taxifolin, catechol. NADH was stoichiometrically oxidized without oxygen uptake which, suggests that

o-quinone metabolites were responsible. GSH was not cooxidized and GSH conjugates were formed, likely mediated by the o-quinone metabolites. Incubation of hepatocytes with dietary polyphenolics containing phenol rings was found to partially oxidize hepatocyte GSH to GSSG while polyphenolics with a catechol ring were found to deplete GSH through formation of GSH conjugates. Dietary polyphenolics with phenol rings also oxidized human erythrocyte oxyHb and caused erythrocyte hemolysis more readily than polyphenolics with catechol rings. It is concluded that polyphenolics containing a phenol ring are generally more prooxidant than polyphenolics containing a catechol ring.

REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 7 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:77951 HCAPLUS
DOCUMENT NUMBER: 134:136704
TITLE: Use of plant polyphenols for treating iron overload
INVENTOR(S): Ghisalberti, Carlo
PATENT ASSIGNEE(S): Medis S.R.L. Medical Infusion Systems, Italy
SOURCE: Eur. Pat. Appl., 13 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1072265	A1	20010131	EP 1999-830464	19990720 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1074254	A2	20010207	EP 2000-115505	20000719 <--
EP 1074254	A3	20020911		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

PRIORITY APPLN. INFO.: EP 1999-830464 A 19990720 <--

AB Comps. and a method of treating iron overloading in human subjects are described, using catechic- and flavonoid-structure plant polyphenols, orally administered alone or in combination thereof, or with common nutritional supplements to enhance the efficacy of prevention of the oxidative metabolic damages caused by excess iron. A capsule composition was prepared containing flavones and flavonols 500 mg, calcium carbonate 250 mg, Mg(OH)₂ 160 mg, Zn subcarbonate 15 mg, β -carotene 5 mg, and α -tocopherol 6 mg, with the balance being a nutritionally acceptable carrier.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 8 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:661792 HCAPLUS
DOCUMENT NUMBER: 133:349576
TITLE: Inhibition of β -carotene-15,15'-dioxygenase activity by dietary flavonoids
AUTHOR(S): Nagao, Akihiko; Maeda, Maki; Lim, Boey Peng; Kobayashi, Hidetaka; Terao, Junji
CORPORATE SOURCE: National Food Research Institute, Ministry of Agriculture, Forestry and Fisheries, Tsukuba, Ibaraki, 305-8642, Japan
SOURCE: Journal of Nutritional Biochemistry (2000), 11(6), 348-355

CODEN: JNBIEL; ISSN: 0955-2863
PUBLISHER: Elsevier Science Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The β -carotene-15,15'-dioxygenase is an enzyme responsible for providing vertebrates with vitamin A by catalyzing oxidative cleavage of β -carotene at its central double bond to 2 mols. of retinal in intestinal cells. We evaluated the effects of antioxidants and dietary flavonoids on the β -carotene dioxygenase activity in vitro using pig intestinal mucosa homogenates as the enzyme source. The synthetic antioxidant 2,6-di-tert-butyl-4-methylphenol (BHT) strongly inhibited the activity at 10^{-6} M (mixed-type inhibition), whereas butylated hydroxyanisole (BHA), nordihydroguaiaretic acid, Pr gallate, and curcumin were moderately inhibitory. Flavonoids (luteolin, quercetin, rhamnetin, phloretin) remarkably inhibited the dioxygenase activity noncompetitively, whereas flavanones, isoflavones, catechins, and anthocyanidins were less inhibitory. The structure-activity relationship indicated that catechol structure of the B ring and planar flavone structure were essential for the inhibition. The enzyme inhibition was also indicated in the cultured Caco-2 cells by the decreased conversion of β -carotene to retinol when incubated with BHT and rhamnetin at 2 and 5 μ M, resp. Thus, some antioxidants from food sources may modulate the conversion of β -carotene to vitamin A in intestinal cells.

REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 9 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:296079 HCAPLUS

DOCUMENT NUMBER: 133:4163

TITLE: Dietary bioflavonoids induce cleavage in the MLL gene and may contribute to infant leukemia

AUTHOR(S): Strick, Reiner; Strissel, Pamela L.; Borgers, Susanne; Smith, Steve L.; Rowley, Janet D.

CORPORATE SOURCE: Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, 60637, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (2000), 97(9), 4790-4795

CODEN: PNASA6; ISSN: 0027-8424

PUBLISHER: National Academy of Sciences

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Chromosomal translocations involving the MLL gene occur in .apprx.80% of infant leukemia. The search for possible agents inducing infant leukemia identified bioflavonoids, natural substances in food and dietary supplements, that cause site-specific DNA cleavage in the MLL breakpoint cluster region (BCR) in vivo. The MLL BCR DNA cleavage was shown in primary progenitor hematopoietic cells from healthy newborns and adults and in cell lines; it colocalized with the MLL BCR cleavage site induced by chemotherapeutic agents, such as etoposide (VP16) and doxorubicin (Dox). Both in vivo and addnl. in vitro expts. demonstrated topoisomerase II (topo II) as the target of bioflavonoids similar to VP16 and Dox. Based on 20 bioflavonoids tested, we identified a common structure essential for the topo II-induced DNA cleavage. Reversibility expts. demonstrated a religation of the bioflavonoid and the VP16-induced MLL cleavage site. The observations support a 2-stage model of cellular processing of topo II inhibitors. The first and reversible stage of topo II-induced DNA cleavage results in DNA repair, but also rarely in chromosome translocations, whereas the second nonreversible stage leads to

cell death because of accumulated DNA damage. Thus, maternal ingestion of bioflavonoids may induce MLL breaks and potentially translocations in utero leading to infant and early childhood leukemia.

REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 10 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:764378 HCAPLUS

DOCUMENT NUMBER: 131:355899

TITLE: Flavonoid compounds and their use, especially in cosmetics

INVENTOR(S): Bresson-Rival, Delphine; Mariotte, Anne-Marie; Boumendjel, Ahcene; Perrier, Eric

PATENT ASSIGNEE(S): Coletica S. A., Fr.

SOURCE: Ger. Offen., 22 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19922287	A1	19991125	DE 1999-19922287	19990514 <--
FR 2778663	A1	19991119	FR 1998-6194	19980515 <--
FR 2778663	B1	20010518		
US 6235294	B1	20010522	US 1998-113158	19980710 <--
JP 2000026263	A2	20000125	JP 1999-136331	19990517 <--
JP 3558922	B2	20040825		
US 2001031735	A1	20011018	US 2001-828986	20010410 <--
US 6471973	B2	20021029		
PRIORITY APPLN. INFO.:			FR 1998-6194	A 19980515 <--
			US 1998-113158	A3 19980710 <--

OTHER SOURCE(S): MARPAT 131:355899

AB 4-Keto flavonoids (phenylchromones) are stabilized for use in cosmetic, pharmaceutical, and dietetic compns. by esterification on a free OH group with a C3-30 monocarboxylic acid without loss of their biol. properties. These esters have enhanced lipid solubility and affinity for cell membranes and the epidermis. Thus, hesperetin 16.55 reacted with lauroyl chloride 26.5 mmol in refluxing PhMe to form dilauroylhesperetin in 64% yield. The diester showed greater radical-scavenging activity than native hesperetin.

L44 ANSWER 11 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:311102 HCAPLUS

DOCUMENT NUMBER: 130:332910

TITLE: Methods and compositions for regulation of 5-alpha reductase activity

INVENTOR(S): Liao, Shutsung; Hiipakka, Richard A.

PATENT ASSIGNEE(S): Arch Development Corporation, USA

SOURCE: PCT Int. Appl., 48 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 8

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9922728	A1	19990514	WO 1998-US23041	19981030 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			

DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,
TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

AU 9912898 A1 19990524 AU 1999-12898 19981030 <--
EP 1027045 A1 20000816 EP 1998-956358 19981030 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, SE, PT, IE
JP 2003524577 T2 20030819 JP 2000-518662 19981030 <--
US 6576660 B1 20030610 US 2000-530443 20000428 <--
US 2003105030 A1 20030605 US 2002-132050 20020424 <--
US 6696484 B2 20040224
US 2003153541 A1 20030814 US 2002-174934 20020619 <--
US 2003144346 A1 20030731 US 2002-294331 20021114 <--
PRIORITY APPLN. INFO.: US 1997-63770P P 19971031 <--
WO 1998-US23041 W 19981030 <--
US 1999-131728P P 19990430 <--
US 2000-530443 A2 20000428 <--
US 2000-560236 A2 20000428 <--
US 2001-267493P P 20010208 <--
US 2001-288643P P 20010503 <--
US 2001-348020P P 20011108 <--
US 2002-72128 A2 20020208 <--
US 2002-137695 A2 20020502 <--

OTHER SOURCE(S): MARPAT 130:332910

AB Comps. that inhibit 5 α -reductase are provided. The comps. are
used to treat prostate cancer, breast cancer, obesity, skin disorders and
baldness.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 12 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:286153 HCAPLUS

DOCUMENT NUMBER: 130:329183

TITLE: Pharmaceutical grade valerian, black cohosh, vitex
agnus-castus, bilberry and milk thistle, and method
for determining thereof

INVENTOR(S): Khwaja, Tasneem A.; Friedman, Elliot P.

PATENT ASSIGNEE(S): Pharmaprint, Inc., USA; University of Southern
California

SOURCE: PCT Int. Appl., 138 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921006	A1	19990429	WO 1998-US22505	19981023 <--
W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,			
	DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE,			
	KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,			
	MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR,			
	TT, UA, UG, US, US, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG,			
	KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,			
	FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,			

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
CA 2307339 AA 19990429 CA 1998-2307339 19981023 <--
AU 9913632 A1 19990510 AU 1999-13632 19981023 <--
PRIORITY APPLN. INFO.: US 1997-955410 A2 19971023 <--
US 1997-955417 A2 19971023 <--
US 1997-956610 A2 19971023 <--
US 1997-956611 A2 19971023 <--
US 1997-956615 A2 19971023 <--
WO 1998-US22505 W 19981023 <--

AB The present invention relates generally to botanical valerian materials and methods for making such materials in medicinally useful and pharmaceutically acceptable forms. More particularly, the present invention relates to the use of compositional and bioactivity fingerprints in the processing of valerian, black cohosh, V. agnus-castus, bilberry or milk thistle materials to produce botanical products, such as drugs, which qualify as pharmaceutical grade compns. which are suitable for use in clin. or veterinary settings to treat and/or ameliorate diseases, disorders or conditions.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 13 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:172375 HCAPLUS

DOCUMENT NUMBER: 130:295991

TITLE: Antioxidant property of dietary phenolic agents in a human LDL-oxidation ex vivo model: interaction of protein binding activity

AUTHOR(S): Wang, Weiqun; Goodman, Marc T.

CORPORATE SOURCE: Cancer Research Center, University of Hawaii, Honolulu, HI, 96813, USA

SOURCE: Nutrition Research (New York) (1999), 19(2), 191-202

CODEN: NTRSDC; ISSN: 0271-5317

PUBLISHER: Elsevier Science Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB High consumption of antioxidant-rich vegetables and fruits has been associated with decreased risk of cardiovascular diseases and cancer. Dietary antioxidants may decrease the risk of atherosclerosis by inhibiting oxidative damage of lipoproteins. Phenolic agents are major dietary antioxidants occurring in high concns. in edible plants. We examined the antioxidant properties of 26 common dietary phenolic agents in a LDL-oxidation ex vivo model. Pooled blood plasma from 22 healthy humans was incubated with 20-200 μ M of each phenolic agent, LDL were then isolated by affinity chromatog. and immediately assessed for oxidative susceptibility by measuring Cu-induced formation of conjugated dienes. All phenolic agents tested showed dose-dependent inhibition of LDL oxidation, varying between 2 and 110% relative to α -tocopherol. In addition to the structural features, the protein binding activity of phenolic agents, as measured with bovine skin proteins as protein matrix, correlated with the antioxidant property ($r = 0.777$). The data not only show the antioxidant property of 26 dietary phenolic agents in this ex vivo model, but also indicate possible involvement of phenol-protein interactions in the biol. inhibition of LDL-oxidation. Both chemical reducing ability and availability at the site of LDL components may be necessary for these major dietary antioxidants to prevent LDL oxidation in vivo.

REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 14 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:696515 HCAPLUS
DOCUMENT NUMBER: 130:80837
TITLE: Inhibition of neoplastic transformation and
bioavailability of dietary flavonoid agents
AUTHOR(S): Franke, Adrian A.; Cooney, Robert V.; Custer, Laurie
J.; Mordan, Lawrence J.; Tanaka, Yuichiro
CORPORATE SOURCE: Cancer Research Center of Hawaii, Honolulu, HI, 96813,
USA
SOURCE: Advances in Experimental Medicine and Biology (
1998), 439(Flavonoids in the Living System),
237-248
CODEN: AEMBAP; ISSN: 0065-2598
PUBLISHER: Plenum Publishing Corp.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Epidemiol. studies show cancer protective effects of fruit and vegetable consumption, but there is little understanding of which phytochemicals account for this observation. Commonly studied antioxidant micronutrients are less consistently correlated with cancer protection relative to the food groups themselves, suggesting that other phytochemicals or a combination of food products play key roles in preventing cancer. We investigated the effects of the main dietary flavonoids and isoflavonoids at inhibiting neoplastic transformation induced by 3-methylcholanthrene in C3H 10T1/2 murine fibroblasts in vitro. Most phenolic agents tested were equal or superior to known chemopreventive agents such as carotenoids or vitamins in their effectiveness. Hesperetin, hesperidin, and catechin were the most potent agents among the flavonoids tested, inhibiting transformation completely when applied at 1.0 μ M after exposure to the carcinogen. Structure-activity comparison revealed that among the compounds tested, flavonoids with a vicinal diphenol structure in the ring B and with saturated ring C had the strongest effects. Most agents tested showed dose-dependent patterns. The soybean isoflavonoids were weakly active except when applied in combination, suggesting a synergistic effect. HPLC techniques were developed for determining the bioavailability of isoflavonoids in human biological fluids including urine, blood plasma, and breast milk. We observed a relatively fast absorption, distribution, and elimination of isoflavonoids including a biphasic pattern probably due to enterohepatic circulation. Total peak isoflavone levels in urine, plasma, and breast milk were 60, 2, and 0.2 μ M, resp., and were reached 8-12 h after the consumption of soybean foods. The levels detected in human body fluids were highly effective at inhibiting the neoplastic transformation, especially considering synergistic effects observed for combinations of daidzein and genistein, the predominant isoflavonoids of soybean foods.

REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 15 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1998:97447 HCAPLUS
DOCUMENT NUMBER: 128:191951
TITLE: Polyphenols in nutrition
AUTHOR(S): German, J. B.; Dillard, C. J.
CORPORATE SOURCE: Department of Food Science and Technology, University
of California, Davis, CA, 95616, USA
SOURCE: Oils-Fats-Lipids 1995, Proceedings of the World
Congress of the International Society for Fat
Research, 21st, The Hague, Oct. 1-6, 1995 (
1996), Meeting Date 1995, Volume 2, 319-322.
P.J. Barnes & Associates: Bridgwater, UK.
CODEN: 65QOAT
DOCUMENT TYPE: Conference; General Review

LANGUAGE: English

AB A review with 13 refs. Considerable interest has focused on the effects of polyphenolic plant metabolites on health due to the recognized neg. association between fruit and vegetable intake and various chronic degenerative diseases. The antioxidant activities of many polyphenols may account mechanistically for at least some of these beneficial effects. Many plant polyphenols also inhibit enzymic reactions and especially oxidant

and signal producing enzymes. Thus, the ability of specific polyphenols to inhibit cyclooxygenase and lipoxygenase enzymes in a dose-dependent manner seen in vitro may account for improvements in blood platelet aggregation in thrombosis, lymphocyte recruitment in inflammatory conditions, and transformed cell proliferation and adhesion in cancer promotion and metastasis. Polyphenols are a diverse group of compds. that includes salicylic, cinnamic, coumaric, and ferulic acid derivs. and gallic esters. In grapes the following phenols have been identified: phenolic acids (hydroxybenzoic, salicylic, cinnamic, coumaric and ferulic derivs., gallic esters), flavonols (kaempferol and quercetin glycosides), flavan-3-ols (catechin, epicatechin, and derivs.), flavanonols (**dihydroquercetin**, dihydrokaempferol, hamnoside) and anthocyanins (cyanidin, peronidine, petunidine, malvidin, coumarin, and caffeine glucosides). It is not yet clear which polyphenols are absorbed by humans, which tissues are affected by them, and whether the initial compds. are converted in vivo to more or less active metabolites. Catechin and its dimers are well absorbed from wine in humans, yet quercetin is very poorly absorbed. Both are readily excreted as metabolites. Full appreciation of the nutritional value of these compds. and avoidance of their potential toxic effects requires detailed investigations of the actions of these mols. according to their chemical structure, tissue concentration, and biol. functions.

REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L44 ANSWER 16 OF 16 HCAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1992:625763 HCAPLUS

DOCUMENT NUMBER: 117:225763

TITLE: Effects of flavonoids on cyclic AMP phosphodiesterase and lipid mobilization in rat adipocytes

AUTHOR(S): Kuppusamy, U. R.; Das, N. P.

CORPORATE SOURCE: Fac. Med., Natl. Univ. Singapore, Singapore, 0511, Singapore

SOURCE: Biochemical Pharmacology (1992), 44(7), 1307-15

CODEN: BCPCA6; ISSN: 0006-2952

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Thirty-one flavonoids were tested for their effects on low-Km phosphodiesterase (PDE) with cAMP as the substrate. Quercetin, luteolin, scutellarein, phloretin and genistein had inhibitory potencies comparable to or greater than that of 3-isobutyl-2-methylxanthine (EC50 30-50 μ M). Only 4 compds. (catechin, epicatechin, taxifolin and fustin) stimulated the enzyme activity (stimulatory EC50 130-240 μ M). The most potent PDE inhibitors were aglycons that had a C2,3 double bond, a keto group at C4 and hydroxyls at C3' and(or) C4'. However, when the C-ring is opened, the requirement for the C2,3 double bond is eliminated. The same series of flavonoids were also tested for their lipolytic activity. The structural features required for effective synergistic lipolysis (with epinephrine) were generally similar to those required for potent PDE inhibition, except that, for lipolytic activity, an intact C-ring was necessary. Fisetin and quercetin, having the above-mentioned structure, caused a concentration- and

time-dependent increase in lipolysis which was synergistic with epinephrine. Only butein and hesperetin caused inhibition of epinephrine-induced lipolysis, and their effect was concentration-dependent. A time-course study indicated that hesperetin was able to delay the lipolytic action of epinephrine. It is most likely that the lipolytic effects of these compds. were not a result of PDE inhibition, as the orders of potency for the 2 activities had poor correlation. Apparently, the effectively lipolytic flavonoids were also potent PDE inhibitors but not all the PDE inhibitors were able to induce lipolysis.

=> d que stat 146

L1 2 SEA FILE=REGISTRY ABB=ON (DIHYDROQUERCETIN OR ARALOSIDE)/CN
 L6 274064 SEA FILE=HCAPLUS ABB=ON OBESITY+ALL/CT
 L7 51039 SEA FILE=HCAPLUS ABB=ON "BODY WEIGHT"+ALL/CT
 L8 39357 SEA FILE=HCAPLUS ABB=ON "BODY FAT"+ALL/CT
 L9 280812 SEA FILE=HCAPLUS ABB=ON L6 OR L7 OR L8
 L10 23 SEA FILE=HCAPLUS ABB=ON L9 AND (L1 OR ?DIHYDROQUERCETIN? OR
 ?ARALOSIDE?)
 L19 1467389 SEA FILE=MEDLINE ABB=ON OBESITY+ALL/CT
 L20 29428 SEA FILE=MEDLINE ABB=ON "BODY WEIGHT: DE, DRUG EFFECTS"/CT
 L21 100 SEA FILE=MEDLINE ABB=ON (?BODY?(W) FAT?(W) ?MASS?) (3A) (?REDUC?
 OR ?REGULAT? OR ?CONTROL?)
 L22 1467429 SEA FILE=MEDLINE ABB=ON L19 OR L20 OR L21
 L23 1 SEA FILE=MEDLINE ABB=ON L22 AND (L1 OR ?DIHYDROQUERCETIN? OR
 ?ARALOSIDE?)
 L31 3 SEA L10
 L32 3 DUP REMOV L31 (0 DUPLICATES REMOVED)
 L33 115470 SEA FILE=HCAPLUS ABB=ON (?OBES? OR ?BODY?) (W) (FAT? OR
 ?WEIGHT?)
 L34 2 SEA FILE=HCAPLUS ABB=ON L33 AND (L1 OR ?DIHYDROQUERCETIN? OR
 ?ARALOSIDE?)
 L36 2 SEA FILE=HCAPLUS ABB=ON L34 AND (L1 OR ?DIHYDROQUERCETIN? OR
 ?ARALOSIDE?)
 L37 2 SEA L36
 L38 2 DUP REMOV L37 (0 DUPLICATES REMOVED)
 L45 4 SEA L23 OR L32 OR L38
 L46 4 DUP REMOV L45 (0 DUPLICATES REMOVED)

=> □

=> d ibib abs 146 1-4

L46 ANSWER 1 OF 4 JICST-EPlus COPYRIGHT 2005 JST on STN
 ACCESSION NUMBER: 1050238644 JICST-EPlus
 TITLE: **Araloside A**, an Antiulcer Constituent from the
 Root Bark of *Aralia elata*
 AUTHOR: LEE E B; KIM O J; KANG S S
 JEONG C
 CORPORATE SOURCE: Seoul National Univ., Seoul, Kor
 Duksung Women's Univ., Seoul, Kor
 SOURCE: Biol Pharm Bull, (2005) vol. 28, no. 3, pp. 523-526.
 Journal Code: S0989A (Fig. 2, Tbl. 6, Ref. 23)
 CODEN: BPLEOT; ISSN: 0918-6158
 PUB. COUNTRY: Japan
 DOCUMENT TYPE: Journal; Short Communication
 LANGUAGE: English
 STATUS: New
 AB **Araloside A**, a potent inhibitor of gastric lesion and ulcer
 formation in rats, was isolated from the root bark of *Aralia elata* through
 a bioassay-guided separation procedure. The compound exhibited significant
 reduction of HCl ethanol-induced gastric lesions and aspirin-induced
 gastric ulcers at oral doses of 50 and 100 mg/kg, respectively. These
 activities are comparable to those of cimetidine. (author abst.)

L46 ANSWER 2 OF 4 MEDLINE on STN
 ACCESSION NUMBER: 2004179939 MEDLINE
 DOCUMENT NUMBER: PubMed ID: 15074660
 TITLE: Effect of flavonoids on feeding preference and development
 of the crucifer pest *Mamestra configurata* Walker.
 AUTHOR: Onyilagha Joseph C; Lazorko Jennifer; Gruber Margaret Y;

CORPORATE SOURCE: Soroka Juliana J; Erlandson Martin A
Agriculture and Agri-Food Canada, Saskatoon Research
Centre, 107 Science Place, Saskatoon, SK S7N 0X2.
SOURCE: Journal of chemical ecology, (2004 Jan) 30 (1) 109-24.
Journal code: 7505563. ISSN: 0098-0331.
PUB. COUNTRY: United States
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)
LANGUAGE: English
FILE SEGMENT: Priority Journals
ENTRY MONTH: 200407
ENTRY DATE: Entered STN: 20040413
Last Updated on STN: 20040728
Entered Medline: 20040726
AB Thirty-seven flavonoid compounds (9 flavones, 18 flavonols, 8 flavanones,
and 2 flavanonols) were investigated for their effect on feeding choice
with bertha armyworm (*Mamestra configurata* Walker; BAW). Feeding choice
was dependent upon subtle differences in biochemical structure.
Unsubstituted flavone and flavanone were the strongest feeding deterrents
in the choice bioassay, while 7.4'-dihydroxyflavone and
dihydroquercetin stimulated BAW to feed. The constitutive
flavonoids of *Brassica napus*, isorhamnetin-3-sophoroside-7-glucoside and
kaempferol-3,7-diglucoside, were effective deterrents when supplemented at
concentrations higher than endogenous levels. In a no-choice bioassay,
flavone reduced both larval weight as well as larval and pupal development
time.

L46 ANSWER 3 OF 4 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN
ACCESSION NUMBER: 2003:471922 BIOSIS
DOCUMENT NUMBER: PREV200300471922
TITLE: Morphological and biochemical responses of the immature
mouse uterus to various phytoestrogens.
AUTHOR(S): Hairston, Alicia [Reprint Author]; Newbold, Retha
CORPORATE SOURCE: Hillside High School, Durham, NC, USA
SOURCE: AAAS Annual Meeting and Science Innovation Exposition,
(21-26 January 1999) Vol. 165, pp. A.95. print.
Meeting Info.: 1999 AAAS Annual Meeting and Science
Innovation Exposition "Challenges for a New Century."
Anaheim, CA, USA. January 21-26, 1999. American Association
for the Advancement of Science.
DOCUMENT TYPE: Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
Conference; (Meeting Poster)
LANGUAGE: English
ENTRY DATE: Entered STN: 15 Oct 2003
Last Updated on STN: 15 Oct 2003

L46 ANSWER 4 OF 4 MEDLINE on STN
ACCESSION NUMBER: 1999111117 MEDLINE
DOCUMENT NUMBER: PubMed ID: 9815559
TITLE: Monohydroxyethylrutoside, a dose-dependent cardioprotective
agent, does not affect the antitumor activity of
doxorubicin.
AUTHOR: van Acker S A; Boven E; Kuiper K; van den Berg D J;
Grimbergen J A; Kramer K; Bast A; van der Vijgh W J
CORPORATE SOURCE: Leiden Amsterdam Center for Drug Research, Division of
Molecular Pharmacology, Department of Pharmacology,
Faculty of Chemistry, Vrije Universiteit, Amsterdam, The
Netherlands.
SOURCE: Clinical cancer research : an official journal of the
American Association for Cancer Research, (1997 Oct) 3 (10)

1747-54.

Journal code: 9502500. ISSN: 1078-0432.

PUB. COUNTRY:

United States

DOCUMENT TYPE:

Journal; Article; (JOURNAL ARTICLE)

LANGUAGE:

English

FILE SEGMENT:

Priority Journals

ENTRY MONTH:

199903

ENTRY DATE:

Entered STN: 19990402

Last Updated on STN: 19990402

Entered Medline: 19990325

AB The cumulative dose-related cardiotoxicity of doxorubicin is believed to be caused by the production of oxygen- free radicals. 7-Monohydroxyethylrutoside (monoHER), a semisynthetic flavonoid and powerful antioxidant, was investigated with respect to the prevention of doxorubicin-induced cardiotoxicity in mice and to its influence on the antitumor activity of doxorubicin in vitro and in vivo. Non-tumor-bearing mice were equipped with a telemeter in the peritoneal cavity. They were given six weekly doses of 4 mg/kg doxorubicin i.v., alone or in combination with either 100 or 250 mg/kg monoHER i.p., 1 h prior to doxorubicin administration and for the following 4 days. Cardiotoxic effects were measured from electrocardiogram changes up to 2 weeks after treatment. Protection against cardiotoxicity was found to be dose dependent, with 53 and 75% protection, respectively, as calculated from the reduction in the increase in the ST interval. MonoHER and several other flavonoids with good antioxidant properties were tested for their antiproliferative effects in the absence or the presence of doxorubicin in A2780 and OVCAR-3 human ovarian cancer cells and MCF-7 human breast cancer cells in vitro. Some flavonoids were directly toxic at 50 and 100 microM, whereas others, including monoHER, did not influence the antiproliferative effects of doxorubicin at these concentrations. The influence of monoHER was further tested on the growth-inhibitory effect of 8 mg/kg doxorubicin i.v., given twice with an interval of 1 week in A2780 and OVCAR-3 cells that were grown as s.c. xenografts in nude mice. MonoHER, administered 1 h before doxorubicin in a dose schedule of 500 mg/kg i.p. 2 or 5 days per week, was not toxic and did not decrease the antitumor activity of doxorubicin. It can be concluded that monoHER showed a dose-dependent protection against chronic cardiotoxicity and did not influence the antitumor activity of doxorubicin in vitro or in vivo.

=> d que stat 143

L1 2 SEA FILE=REGISTRY ABB=ON (DIHYDROQUERCETIN OR ARALOSIDE)/CN
 L6 274064 SEA FILE=HCAPLUS ABB=ON OBESITY+ALL/CT
 L7 51039 SEA FILE=HCAPLUS ABB=ON "BODY WEIGHT"+ALL/CT
 L8 39357 SEA FILE=HCAPLUS ABB=ON "BODY FAT"+ALL/CT
 L9 280812 SEA FILE=HCAPLUS ABB=ON L6 OR L7 OR L8
 L10 23 SEA FILE=HCAPLUS ABB=ON L9 AND (L1 OR ?DIHYDROQUERCETIN? OR
 ?ARALOSIDE?)
 L33 115470 SEA FILE=HCAPLUS ABB=ON (?OBES? OR ?BODY?) (W) (FAT? OR
 ?WEIGHT?)
 L34 2 SEA FILE=HCAPLUS ABB=ON L33 AND (L1 OR ?DIHYDROQUERCETIN? OR
 ?ARALOSIDE?)
 L39 1 SEA FILE=USPATFULL ABB=ON L10 AND (PRD<20030106 OR PD<20030106
)
 L40 47 SEA FILE=USPATFULL ABB=ON L34 AND (L1 OR ?DIHYDROQUERCETIN?
 OR ?ARALOSIDE?)
 L41 47 SEA FILE=USPATFULL ABB=ON L39 OR L40
 L42 42 SEA FILE=USPATFULL ABB=ON L41 AND ?MAMMAL?
 L43 42 SEA FILE=USPATFULL ABB=ON L42 AND ?METHOD?

=> d ibib abs 143 1-42

L43 ANSWER 1 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2005:275158 USPATFULL

 TITLE: **Methods** for the treatment of peripheral
 neural and vascular ailments

INVENTOR(S): Rosenbloom, Richard A., Elkins Park, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005239721	A1	20051027
APPLICATION INFO.:	US 2005-165151	A1	20050623 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-288825, filed on 6 Nov 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KNOBLE, YOSHIDA & DUNLEAVY, EIGHT PENN CENTER, SUITE 1350, 1628 JOHN F KENNEDY BLVD, PHILADELPHIA, PA, 19103, US		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
LINE COUNT:	970		

AB Compositions and **methods** for the treatment of peripheral
 neural and vascular ailments are disclosed. The **method**
 comprises administering a flavonoid compound with antioxidant
 properties, optionally formulated in a acceptable carrier. This compound
 or combination of compounds provides significant, effective relief of
 the symptoms of peripheral neural or vascular ailments. In addition, the
 compositions, when used according to the **methods** of the
 present invention, do not exhibit the severe side effects of many prior
 art compositions proposed for treatment of these ailments.

L43 ANSWER 2 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2005:248295 USPATFULL

 TITLE: Calcium-containing tissue strengthening agents and use
 thereof

 INVENTOR(S): Miyake, Masaki, Okayama, JAPAN
 Ushio, Shimpei, Okayama, JAPAN
 Iwaki, Kanso, Okayama, JAPAN

Kurimoto, Masashi, Okayama, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005215493	A1	20050929
APPLICATION INFO.:	US 2003-513119	A1	20020502 (10)
	WO 2002-JP4407		20020502
			20041101 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-2002130154	20020501
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Browdy and Neimark, 624 Ninth Street N W, Suite 300, Washington, DC, 20001-5303, US	
NUMBER OF CLAIMS:	15	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	1097	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention has an object to provide an agent for strengthening calcium-containing tissues, which can be safely applied; and its use: The present invention solves the object by providing an agent for strengthening calcium-containing tissues, which comprises one or more flavones, flavonols, flavanones, flavanonols, anthocyanidins, flavanols, chalcones, and aurones.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 3 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2005:241167 USPATFULL
 TITLE: Treatment of periodontal disease
 INVENTOR(S): Romanczyk, Leo J. JR., Hackettstown, NJ, UNITED STATES
 Schmitz, Harold H., Bethesda, MD, UNITED STATES
 PATENT ASSIGNEE(S): Mars, Incorporated, McLean, VA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005209171	A1	20050922
APPLICATION INFO.:	US 2004-4677	A1	20041203 (11)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-795552, filed on 8 Mar 2004, PENDING Continuation of Ser. No. US 2004-770969, filed on 2 Feb 2004, GRANTED, Pat. No. US 6900241 Division of Ser. No. US 2002-127817, filed on 22 Apr 2002, PENDING Continuation of Ser. No. US 2001-776649, filed on 5 Feb 2001, GRANTED, Pat. No. US 6638971 Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, GRANTED, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NADA JAIN, P.C., 560 White Plains Road, Suite 460, Tarrytown, NY, 10591, US		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1-208		
NUMBER OF DRAWINGS:	242 Drawing Page(s)		
LINE COUNT:	4540		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed and claimed are cocoa extracts, compounds, combinations thereof and compositions containing the same, such as polyphenols or procyanidins, **methods** for preparing such extracts, compounds and compositions, as well as uses for them, especially a polymeric compound of the formula A.sub.n, wherein A is a monomer of the formula: ##STR1## wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units; R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar; bonding between adjacent monomers takes place at positions 4, 6 or 8; a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry; X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto (the bonding of the additional monomeric unit adjacent to the terminal monomeric unit) is at position 4 and optionally Y=Z=hydrogen; the sugar is optionally substituted with a phenolic moiety, at any position on the sugar, for instance via an ester bond, and pharmaceutically acceptable salts or derivatives thereof (including oxidation products).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 4 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2005:208496 USPATFULL

TITLE: Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders

INVENTOR(S): Wahl, Alan F., Mercer Island, WA, UNITED STATES
Senter, Peter D., Seattle, WA, UNITED STATES
Law, Che-Leung, North Shoreline, WA, UNITED STATES
Cervený, Charles G., Seattle, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005180972	A1	20050818
APPLICATION INFO.:	US 2003-632151	A1	20030730 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-400404P	20020731 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	49	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	5861	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to **methods** and compositions for the treatment of CD20-expressing cancers and immune disorders involving CD20-expressing cells. The present **methods** comprise administering to a subject an anti CD20 antibody-drug conjugate that has a high potency and/or is capable of internalizing into CD20-expressing cells. The present invention further provides pharmaceutical compositions and kits comprising such conjugates. The present invention yet further provides **methods** of and compositions relating to combination therapy of cancer and immune disorders involving CD20-expressing cells using the anti-CD20 antibody-drug conjugates of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 5 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2005:159043 USPATFULL

TITLE: Formulations and **methods** for treatment or amelioration of inflammatory conditions

INVENTOR(S): Phinney, Stephen Dodge, Elk Grove, CA, UNITED STATES
Dreon, Darlene M., Menlo Park, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005137253	A1	20050623
APPLICATION INFO.:	US 2004-967105	A1	20041015 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-295493, filed on 15 Nov 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-335545P	20011115 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY & LARDNER LLP, 1530 PAGE MILL ROAD, PALO ALTO, CA, 94304, US	
NUMBER OF CLAIMS:	53	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2716	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations and **methods** for the treatment and/or amelioration of symptoms of inflammatory conditions and associated systemic inflammatory responses are described herein. The compositions comprise a non-alpha tocopherol (especially gamma-, beta-, or delta-tocopherol) and one or more of an omega-3 fatty acid, such as docosahexaenoic acid (DHA) or a flavonoid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 6 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2005:143801 USPATFULL

TITLE: Treatment of immunological disorders using anti-dc30 antibodies

INVENTOR(S): Law, Che-Leung, North Shoreline, WA, UNITED STATES
Klussman, Kerry, Seattle, WA, UNITED STATES
Wahl, Alan F., Mercer Island, WA, UNITED STATES
Senter, Peter, Seattle, WA, UNITED STATES
Doronina, Svetlana, Seattle, WA, UNITED STATES
Toki, Brian, Everett, WA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005123536	A1	20050609
APPLICATION INFO.:	US 2003-496628	A1	20021120 (10)
	WO 2002-US37223		20021120

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-331750P	20011120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	JONES DAY, 222 EAST 41ST ST, NEW YORK, NY, 10017, US	
NUMBER OF CLAIMS:	210	

EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Page(s)
LINE COUNT: 5592
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to **methods** for the treatment of immunological disorders other than cancer, comprising administering proteins characterized by their ability to bind to CD30 and exert a cytostatic or cytotoxic effect on an activated lymphocyte. Such proteins include monoclonal antibodies AC10 and IleFi1. AC10 and HeFi-1 derivatives, and antibodies that compete with AC10 and HeFi-1 for binding to CD30. Other such proteins include multivalent anti-CD30 antibodies and anti-CD30 antibodies conjugated to cytotoxic agents. Treatment modalities with antibodies of the invention are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 7 OF 42 USPATFULL on STN
ACCESSION NUMBER: 2005:99621 USPATFULL
TITLE: Compounds and **methods** for delivery of prostacyclin analogs
INVENTOR(S): Phares, Ken, Chapel Hill, NC, UNITED STATES
Mottola, David, Cary, NC, UNITED STATES
PATENT ASSIGNEE(S): UNITED THERAPEUTICS CORPORATION (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085540	A1	20050421
APPLICATION INFO.:	US 2004-851481	A1	20040524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-472407P	20030522 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FOLEY AND LARDNER, SUITE 500, 3000 K STREET NW, WASHINGTON, DC, 20007, US	
NUMBER OF CLAIMS:	51	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Page(s)	
LINE COUNT:	2722	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention pertains generally to prostacyclin analogs and **methods** for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis. Generally, the compounds and **methods** of the present invention increase the oral bioavailability and circulating concentrations of treprostinil when administered orally. Compounds of the present invention have the following formula: ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 8 OF 42 USPATFULL on STN
ACCESSION NUMBER: 2005:99512 USPATFULL
TITLE: Treatment of hypertension
INVENTOR(S): Romanczyk, Leo J. JR., Hackettstown, NJ, UNITED STATES
Schmitz, Harold H., Bethesda, MD, UNITED STATES
PATENT ASSIGNEE(S): Mars, Incorporated, McLean, VA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005085431	A1	20050421
APPLICATION INFO.:	US 2004-795552	A1	20040308 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2004-770969, filed on 6 May 2004, PENDING Division of Ser. No. US 2002-127817, filed on 22 Apr 2002, PENDING Continuation of Ser. No. US 2001-776649, filed on 5 Feb 2001, GRANTED, Pat. No. US 6638971 Continuation of Ser. No. US 2000-717893, filed on 21 Nov 2000, GRANTED, Pat. No. US 6670390 Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, GRANTED, Pat. No. US 6297273 Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, GRANTED, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NADA JAIN, P.C., 560 White Plains Road, Suite 460, Tarrytown, NY, 10591, US		
NUMBER OF CLAIMS:	70		
EXEMPLARY CLAIM:	1-208		
NUMBER OF DRAWINGS:	242 Drawing Page(s)		
LINE COUNT:	4754		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Polyphenol-containing compositions, for example procyanidins and derivatives thereof, and their use for treating hypertension are disclosed. Compositions may be used for human and veterinary use, and may be, for example, in a form of a food, a dietary supplement or a pharmaceutical.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 9 OF 42 USPATFULL on STN

ACCESSION NUMBER:	2005:50607	USPATFULL
TITLE:	Anti-glycation agents for preventing age- diabetes- and smoking-related complications	
INVENTOR(S):	Yeboah, Faustinus, Longueuil, SWITZERLAND Konishi, Yasuo, Kirkland, CANADA Cho, Sung Ju, Montreal, CANADA Lertvorachon, Jittiwud, Montreal, CANADA Kiyota, Taira, St. Laurent, CANADA Tomasz, Popek, Pointe-Claire, CANADA	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005043408	A1	20050224
APPLICATION INFO.:	US 2004-492553	A1	20041008 (10)
	WO 2002-CA1552		20021015

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-328808P	20011015 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BORDEN LADNER GERVAIS LLP, WORLD EXCHANGE PLAZA, 100 QUEEN STREET SUITE 1100, OTTAWA, ON, K1P 1J9	
NUMBER OF CLAIMS:	37	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	

LINE COUNT: 1276

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides new inhibitors of protein glycation, identified from compound libraries by a high throughput screening assay. The anti-glycation agents so identified are characterized by a variety of chemical structures and are useful for the prevention or treatment of age-, diabetes-, and smoking-related complications, including neuropathy, nephropathy, ocular pathologies, or the loss of mechanical properties of collagenous tissues. Among compounds identified as having the anti-glycation activity, of special interest are epinephrine and its analogs, in particular D-epinephrine and its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and smoking-related ocular pathologies.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 10 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2005:49519 USPATFULL

TITLE: Use of an opuntia ficus-indica extract and compounds isolated therefrom for protecting nerve cells

INVENTOR(S): Lee, Yong Sup, Seoul, KOREA, REPUBLIC OF
Park, Hokoon, Seoul, KOREA, REPUBLIC OF
Jin, Changbae, Seoul, KOREA, REPUBLIC OF
Cho, Jungsook, Kyungaangbuk-do, KOREA, REPUBLIC OF
Park, Mijeong, Daejon, KOREA, REPUBLIC OF
Song, Yunaaon, Seoul, KOREA, REPUBLIC OF

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005042311	A1	20050224
APPLICATION INFO.:	US 2004-493748	A1	20041012 (10)
	WO 2002-KR2010		20021029

	NUMBER	DATE
PRIORITY INFORMATION:	KR 2001-66810	20011029
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, LLP, 1300 I STREET, NW, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	916	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a use of an ethyl acetate extract of Opuntia ficus-indica and compounds isolated therefrom for preventing and treating brain diseases such as Alzheimer's disease, stroke and Parkinson's disease, cell and tissue damage caused by ischemia, or cardiovascular system disease such as myocardial infarction.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 11 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2004:327988 USPATFULL

TITLE: Treatment of bladder and urinary tract cancers

INVENTOR(S): Zi, Xiolin, Irvine, CA, UNITED STATES
Simoneau, Anne R., Long Beach, CA, UNITED STATES

PATENT ASSIGNEE(S): The Regents of the University of California, Oakland,
CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004259813	A1	20041223
APPLICATION INFO.:	US 2004-817449	A1	20040401 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-459495P	20030401 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Robert D. Buyan, Stout, Uxa, Buyan & Mullins, LLP, Suite 300, 4 Venture, Irvine, CA, 92618	
NUMBER OF CLAIMS:	21	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	611	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions of matter and **methods** wherein chalcone and flavone derivatives are administered to human or veterinary patients for the treatment of bladder or urinary tract cancer. Compounds of the invention include 2'-hydroxy-4,4',6'-trimethoxychalcone (Flavokawain A).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 12 OF 42 USPATFULL on STN
ACCESSION NUMBER: 2004:281091 USPATFULL
TITLE: Compositions for, and **methods** of, treating atherosclerosis
INVENTOR(S): Romanczyk,, Leo J., JR., Hackettstown, NJ, UNITED STATES
Schmitz, Harold H., Branchburg, NJ, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004220392	A1	20041104
	US 6900241	B2	20050531
APPLICATION INFO.:	US 2004-770969	A1	20040506 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2002-127817, filed on 22 Apr 2002, PENDING Continuation of Ser. No. US 2001-776649, filed on 5 Feb 2001, GRANTED, Pat. No. US 6638971 Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, GRANTED, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, ABANDONED Continuation of Ser. No. US 2000-717893, filed on 21 Nov 2000, GRANTED, Pat. No. US 6670390 Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, GRANTED, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NADA JAIN, P.C., 560 White Plains Road, Suite 460, Tarrytown, NY, 10591		
NUMBER OF CLAIMS:	17		
EXEMPLARY CLAIM:	CLM-1-208		
NUMBER OF DRAWINGS:	242 Drawing Page(s)		
LINE COUNT:	4732		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed and claimed are cocoa extracts, compounds, combinations

thereof and compositions containing the same, such as polyphenols or procyanidins, **methods** for preparing such extracts, compounds and compositions, as well as uses for them, especially a polymeric compound of the formula A.sub.n, wherein A is a monomer of the formula: ##STR1##

wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;

R is 3-(α)-OH, 3-(β)-OH, 3-(α)-o-sugar, or 3-(β)-O-sugar;

bonding between adjacent monomers takes place at positions 4, 6 or 8;

a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;

X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto (the bonding of the additional monomeric unit adjacent to the terminal monomeric unit) is at position 4 and optionally Y=Z=hydrogen;

the sugar is optionally substituted with a phenolic moiety, at any position on the sugar, for instance via an ester bond, and

pharmaceutically acceptable salts or derivatives thereof (including oxidation products).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 13 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2004:273337 USPATFULL

TITLE: Dietary supplement

INVENTOR(S): Coleman, Henry D., Hastings, NY, UNITED STATES

Sudol, R. Neil, Scarsdale, NY, UNITED STATES

Sapone, William J., Southport, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004213829	A1	20041028
APPLICATION INFO.:	US 2004-852391	A1	20040524 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-123576, filed on 15 Apr 2002, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	WILLIAM J. SAPONE, COLEMAN SUDOL SAPONE P.C., 714 COLORADO AVENUE, BRIDGE PORT, CT, 06605		
NUMBER OF CLAIMS:	31		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1162		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dietary supplement, preferably formulated with a confectionery base, removes or prevents the bio-accumulation of heavy metals in the body. The supplement has one or more natural chelators, or precursors therefore, with at least one chelator capable of crossing the blood brain barrier to capture a heavy metal ion from a site in the central nervous system. The chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. Preferably, one or more

secondary chelators bind any of the heavy metal released from the primary chelator and hold it for removal via an excretion pathway. In one embodiment, the supplement includes glutathione or metallothioneine to assist in moving the chelated heavy metal out into the excretion pathway. Using the dietary supplement limits the accumulation of heavy metals in the body, promotes removal of heavy metals previously accumulated in the body and thereby alleviates the symptoms and conditions associated with heavy metal toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 14 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2004:239253 USPATFULL
 TITLE: Therapeutical vaccination
 INVENTOR(S): Kirkby, Nikolai Soren, Copenhagen, DENMARK
 Dalsgaard, Kristian, Kalvehave, DENMARK

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004185057	A1	20040923
APPLICATION INFO.:	US 2003-480534	A1	20031212 (10)
	WO 2002-DK404		20020614

	NUMBER	DATE
PRIORITY INFORMATION:	DK 2001-939	20010615
	US 2001-60300095	20010625
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BIRCH STEWART KOLASCH & BIRCH, PO BOX 747, FALLS CHURCH, VA, 22040-0747	
NUMBER OF CLAIMS:	98	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	3860	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes a therapeutic approach by which malignant or other diseased tissues are at least partly eliminated or removed by action of the diseased individuals own immune system. Provided that the diseased tissue is a cancer the present invention relates to the field of cancer immunotherapy. The basic principle of the invention relies on the establishment of an immune response in the diseased individual against a selected antigen. This is followed by the transfer of the antigen to the diseased cells of the individual by which the elicited immune response is directed against the diseased cells whereby the diseased tissue is eliminated. The immunogen used to induce the immunological response may be, but is not required to be, identical to the antigen. The immuneresponse may exist prior to treatment due to natural infections or may be established by vaccination or by a combination hereof. However, for some applications the active immune component may be provided from heterologous sources and transferred to the individual undergoing treatment e.g. passive transfer of antibodies obtained from another individual or animal or by means of recombinant technology.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 15 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2004:190687 USPATFULL
 TITLE: Novel composition for the treatment of obesity and

effective fat loss promotion
 INVENTOR(S): Ramazanov, Arthur, Warwick, NY, UNITED STATES
 Ramazanov, Zakir, Warwick, NY, UNITED STATES
 PATENT ASSIGNEE(S): National Bioscience Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004147460	A1	20040729
APPLICATION INFO.:	US 2003-660256	A1	20030911 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-438113P	20030106 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	DARBY & DARBY P.C., Post Office Box 5257, New York, NY, 10150-5257	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	986	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention encompasses pharmaceutical compositions for the treatment of obesity. These compositions comprise **dihydroquercetins** (**dihydroquercetin** 3-rhamnoside and its aglycon **dihydroquercetin**) and the triterpene saponins known as **aralosides** or **elatosides**. The compositions of the present invention effectively promote total weight loss and **body fat** mass loss. Therefore, the present invention is also directed to **methods** for treating obesity, reducing total weight, and reducing **body fat** mass by administering the compositions of the invention. The invention also embraces **methods** for disrupting the perilipin shell of lipid droplets and stimulating the activity of hormone-sensitive lipase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 16 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2004:114670 USPATFULL

TITLE: **Methods** for the treatment of peripheral neural and vascular ailments

INVENTOR(S): Rosenbloom, Richard A., Elkins Park, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004087516	A1	20040506
APPLICATION INFO.:	US 2002-288825	A1	20021106 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Kevin J. Dunleavy, KNOBLE & YOSHIDA, LLC, Eight Penn Center, 1628 John F. Kennedy Blvd., Philadelphia, PA, 19103		
NUMBER OF CLAIMS:	29		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1022		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and **methods** for the treatment of peripheral neural and vascular ailments are disclosed. The **method** comprises administering a flavonoid compound with antioxidant properties, optionally formulated in a acceptable carrier. This compound

or combination of compounds provides significant, effective relief of the symptoms of peripheral neural or vascular ailments. In addition, the compositions, when used according to the **methods** of the present invention, do not exhibit the severe side effects of many prior art compositions proposed for treatment of these ailments.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 17 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2004:64400 USPATFULL

TITLE: Compositions and **methods** for reduction of inflammatory symptoms and/or biomarkers in female subjects

INVENTOR(S): Dreon, Darlene M., Menlo Park, CA, UNITED STATES
Phinney, Stephen Dodge, Elk Grove, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004048919	A1	20040311
APPLICATION INFO.:	US 2003-612118	A1	20030702 (10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2002-393550P	20020702 (60)	<--
	US 2003-461325P	20030408 (60)	

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: GALILEO PHARMACEUTICALS, INC., (PREVIOUSLY GALILEO LABORATORIES, INC.), 5301 PATRICK HENRY DRIVE, SANTA CLARA, CA, 95954

NUMBER OF CLAIMS: 74

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 3 Drawing Page(s)

LINE COUNT: 2282

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Medicaments and **methods** for the treatment and/or amelioration of certain inflammatory symptoms related to premenstrual syndrome (PMS), premenstrual dysphoric disorder (PMDD), perimenopause, menopause, endometriosis, post-partum depression, or administration of hormonal contraceptives are described herein. Medicaments of the invention comprise a tocopherol, an omega-3 polyunsaturated fatty acid, such as docosahexaenoic acid (DHA), or omega-9 polyunsaturated fatty acid, optionally, a flavonoid, and, optionally, a mineral, such as magnesium. **Methods** for treating or ameliorating such symptoms and **methods** for reducing elevated CRP and/or white blood cell (WBC) associated with such conditions using medicaments of the invention are also described.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 18 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2004:46811 USPATFULL

TITLE: Procyanidin and cyclo-oxygenase modulator compositions

INVENTOR(S): Romanczyk, Jr., Leo J., Hackettstown, NJ, United States
Schmitz, Harold H., Branchburg, NJ, United States

PATENT ASSIGNEE(S): Mars, Incorporated, McLean, VA, United States (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 6696485 B1 20040224
APPLICATION INFO.: US 2002-268718 20021010 (10)
RELATED APPLN. INFO.: Continuation of Ser. No. US 2000-717893, filed on 21
Nov 2000 Continuation of Ser. No. US 2001-776649, filed
on 5 Feb 2001 Continuation of Ser. No. US 2002-127817,
filed on 22 Apr 2002

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Solola, Taofiq
LEGAL REPRESENTATIVE: Nada Jain, P.C., Jain, Nada
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 54 Drawing Figure(s); 241 Drawing Page(s)
LINE COUNT: 4397

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to compositions comprising a cyclo-oxygenase
modulator in combination with cocoa procyanidin monomers and/or
oligomers, wherein the cyclo-oxygenase modulator is a non-steroidal
anti-inflammatory drug such as aspirin. Such compositions may be used
for the treatment of cardiovascular related disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 19 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:337302 USPATFULL

TITLE: Cocoa extract compounds and **methods** for
making and using the same

INVENTOR(S): Romanczyk, Jr., Leo J., Hackettstown, NJ, United States
Hammerstone, Jr., John F., Nazareth, PA, United States
Buck, Margaret M., Morristown, NJ, United States
Post, Laurie S., Great Meadows, NJ, United States
Cipolla, Giovanni G., Alpha, NJ, United States
McClelland, Craig A., East Stroudsburg, PA, United
States

Mundt, Jeff A., Hackettstown, NJ, United States
Schmitz, Harold H., Branchburg, NJ, United States
PATENT ASSIGNEE(S): Mars Incorporated, McLean, VA, United States (U.S.
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6670390	B1	20031230
APPLICATION INFO.:	US 2000-717893		20001121 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, now patented, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Solola, T. A.		
LEGAL REPRESENTATIVE:	Kelley, Margaret B., Clifford Chance Rogers & Wells		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	248 Drawing Figure(s); 232 Drawing Page(s)		
LINE COUNT:	4609		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed and claimed are cocoa extracts, compounds, combinations
thereof and compositions containing the same, such as polyphenols or
procyanidins, **methods** for preparing such extracts, compounds
and compositions, as well as uses for them, especially a polymeric

compound of the formula A.sub.n, wherein A is a monomer of the formula:
##STR1##

wherein

n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;

R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or
3-(β)-O-sugar.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 20 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:288211 USPATFULL

TITLE: Enhancing therapeutic effectiveness of nitric oxide inhalation

INVENTOR(S): Bloch, Kenneth D., Brookline, MA, UNITED STATES
Ichinose, Fumito, Brookline, MA, UNITED STATES
Zapol, Warren M., Concord, MA, UNITED STATES

PATENT ASSIGNEE(S): The General Hospital Corporation (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003202969	A1	20031030
	US 6935334	B2	20050830
APPLICATION INFO.:	US 2003-458578	A1	20030609 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-605900, filed on 28 Jun 2000, GRANTED, Pat. No. US 6601580		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Page(s)		
LINE COUNT:	1426		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Methods** for reducing, partially preventing or completely preventing nitric oxide (NO) inhalation-related impairment of HPV in a **mammal** are disclosed. The **methods** include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-reactive oxygen species (anti-ROS) agent, e.g., N-acetylcysteine, or a leukotriene blocker. **Methods** for reducing, partially preventing or completely preventing loss of pulmonary vasodilatory responsiveness to NO inhalation in a **mammal** are also disclosed. The **methods** include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-ROS agent a therapeutically effective amount of a leukotriene blocker.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 21 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:276428 USPATFULL

TITLE: Dietary supplement

INVENTOR(S): Coleman, Henry D., Hastings, NY, UNITED STATES
Sudol, R. Neil, Scarsdale, NY, UNITED STATES
Sapone, William J., Southport, CT, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003194453	A1	20031016
APPLICATION INFO.:	US 2002-123576	A1	20020415 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	William J. Sapone, Esq., Coleman Sudol Sapone P.C., 714 Colorado Ave., Bridgeport, CT, 06605		
NUMBER OF CLAIMS:	51		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1149		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A dietary supplement for removing or preventing the bio-accumulation of heavy metals in the body includes a primary chelator, a secondary chelator, and optionally a tertiary chelator or a precursor of a tertiary chelator. The primary chelator preferably crosses the blood brain barrier to capture a heavy metal ion from a site in the central nervous system. The primary chelator then crosses back through the blood brain barrier with the entrained heavy metal ion. The secondary chelator binds the heavy metal from or with the primary chelator for removal. In one embodiment, a tertiary chelator such as glutathione or metallothionine assists in moving the chelated heavy metal out into an excretion pathway. Using the dietary supplement limits the accumulation of heavy metals in the body, promotes removal of heavy metals previously accumulated in the body and alleviates the symptoms and conditions associated with heavy metal toxicity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 22 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:209465 USPATFULL
 TITLE: Enhancing therapeutic effectiveness of nitric oxide inhalation
 INVENTOR(S): Bloch, Kenneth D., Brookline, MA, United States
 Ichinose, Fumito, Brookline, MA, United States
 Zapol, Warren M., Concord, MA, United States
 PATENT ASSIGNEE(S): The General Hospital Corporation, Boston, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6601580	B1	20030805
APPLICATION INFO.:	US 2000-605900		20000628 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Weber, Jon P.		
ASSISTANT EXAMINER:	Patten, Patricia A		
LEGAL REPRESENTATIVE:	Fish & Richardson P.C.		
NUMBER OF CLAIMS:	36		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	18 Drawing Figure(s); 13 Drawing Page(s)		
LINE COUNT:	1546		

AB **Methods** for reducing, partially preventing or completely preventing nitric oxide (NO) inhalation-related impairment of HPV in a **mammal** are disclosed. The **methods** include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-reactive oxygen species (anti-ROS) agent, e.g., N-acetylcysteine, or a leukotriene blocker. **Methods** for reducing, partially preventing or

completely preventing loss of pulmonary vasodilatory responsiveness to NO inhalation in a **mammal** are also disclosed. The **methods** include administering a therapeutically effective amount of NO by inhalation, and co-administering an effective amount of an anti-ROS agent a therapeutically effective amount of a leukotriene blocker.

L43 ANSWER 23 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:207985 USPATFULL

TITLE: **Methods** and compositions for regulation of 5-alpha reductase activity

INVENTOR(S): Liao, Shutsung, Chicago, IL, UNITED STATES
Hiipakka, Richard A., Chicago, IL, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144346	A1	20030731
APPLICATION INFO.:	US 2002-294331	A1	20021114 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-530443, filed on 28 Apr 2000, PENDING A 371 of International Ser. No. WO 1998-US23041, filed on 30 Oct 1998, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-63770P	19971031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MAYER, BROWN, ROWE & MAW, P.O. BOX 2828, CHICAGO, IL, 60690	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	1120	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that inhibit 5 α -reductase are provided. The compounds are used to treat prostate cancer, breast cancer, obesity, skin disorders and baldness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 24 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:207858 USPATFULL

TITLE: Formulations and **methods** for treatment or amelioration of inflammatory conditions

INVENTOR(S): Phinney, Stephen Dodge, Elk Grove, CA, UNITED STATES
Dreon, Darlene M., Menlo Park, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003144219	A1	20030731
APPLICATION INFO.:	US 2002-295493	A1	20021115 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-335545P	20011115 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GALILEO PHARMACEUTICALS, INC., (PREVIOUSLY GALILEO LABORATORIES, INC.), 5301 PATRICK HENRY DRIVE, SANTA	

CLARA, CA, 95954
NUMBER OF CLAIMS: 46
EXEMPLARY CLAIM: 1
LINE COUNT: 2711

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations and **methods** for the treatment and/or amelioration of symptoms of inflammatory conditions and associated systemic inflammatory responses are described herein. The compositions comprise a non-alpha tocopherol (especially gamma-, beta-, or delta-tocopherol) and one or more of an omega-3 fatty acid, such as docosahexaenoic acid (DHA) or a flavonoid.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 25 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:172692 USPATFULL

TITLE: Topical compositions and **methods** for treatment of adverse effects of ionizing radiation

INVENTOR(S): Rosenbloom, Richard A., Elkins Park, PA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003118536	A1	20030626
APPLICATION INFO.:	US 2002-288761	A1	20021106 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-132642, filed on 25 Apr 2002, PENDING Continuation-in-part of Ser. No. US 2002-45790, filed on 14 Jan 2002, PENDING Continuation-in-part of Ser. No. US 2001-993003, filed on 6 Nov 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	KNOBLE & YOSHIDA, EIGHT PENN CENTER, SUITE 1350, 1628 JOHN F KENNEDY BLVD, PHILADELPHIA, PA, 19103		
NUMBER OF CLAIMS:	40		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1162		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and **methods** for the prevention, reduction or treatment of adverse effects due to exposure to ionizing radiation, including at least one flavonoid and at least one non-flavonoid antioxidant, optionally formulated in a acceptable carrier for a topical composition. The composition of the present invention may further include optional ingredients such as selenium, selenium compounds, anti-inflammatories, organic germanium compounds, compounds that regulate cell differentiation, Korean ginseng, American ginseng, Siberian ginseng and B-complex vitamins. A **method** for the topical administration of the composition in accordance with the present invention for the purpose of reducing, treating or preventing adverse effects caused by ionizing radiation involves topically administering a safe and effective amount of the composition of the invention an area of skin, which has been, is being or will be exposed to ionizing radiation. The compositions and **methods** can be employed to reduce, treat or prevent radiation injury caused by a wide variety of types of exposure to ionizing radiation.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 26 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:169023 USPATFULL

TITLE: Chondroprotective agents

INVENTOR(S): Watanabe, Koju, Saitama, JAPAN
 Niimura, Koichi, Saitama, JAPAN
 Umekawa, Kiyonori, Chiba, JAPAN
 PATENT ASSIGNEE(S): Kureha Chemical Industry Co., Ltd., Tokyo, JAPAN
 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6583118	B1	20030624
APPLICATION INFO.:	US 1997-805049		19970224 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-519179, filed on 25 Aug 1995, now patented, Pat. No. US 5650433, issued on 22 Jul 1997 Continuation of Ser. No. US 1994-271951, filed on 8 Jul 1994, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-194182	19930709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Sughrue Mion, PLLC	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	398	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A chondroprotective agent comprising a flavonoid compound of the general formula (I): ##STR1##

wherein R.sup.1 to R.sup.9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to protect cartilage, and thus, is extremely effective for the treatment of arthropathy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 27 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:165436 USPATFULL

TITLE: Cocoa extract compounds and **methods** for making and using the same

INVENTOR(S): Romanczyk,, Leo J., JR., Hackettstown, NJ, UNITED STATES

Schmitz, Harold H., Branchburg, NJ, UNITED STATES
 PATENT ASSIGNEE(S): MARS Incorporated (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003113290	A1	20030619
APPLICATION INFO.:	US 2002-127817	A1	20020422 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-776649, filed on 5 Feb 2001, PENDING Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, GRANTED, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, ABANDONED Continuation of Ser. No. US 2000-717893, filed on 21 Nov 2000, PENDING Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997,		

DOCUMENT TYPE: GRANTED, Pat. No. US 6297273 Continuation-in-part of
FILE SEGMENT: Ser. No. US 1996-631661, filed on 2 Apr 1996, ABANDONED
UTILITY
LEGAL REPRESENTATIVE: APPLICATION
CLIFFORD CHANCE US LLP, 200 PARK AVENUE, NEW YORK, NY,
10166
NUMBER OF CLAIMS: 208
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 258 Drawing Page(s)
LINE COUNT: 6136
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed and claimed are cocoa extracts, compounds, combinations thereof and compositions containing the same, such as polyphenols or procyanidins, **methods** for preparing such extracts, compounds and compositions, as well as uses for them, especially a polymeric compound of the formula A.sub.n, wherein A is a monomer of the formula: ##STR1##

wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;

R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;

bonding between adjacent monomers takes place at positions 4, 6 or 8;

a bond of an additional monomeric unit in position 4 has alpha or beta stereochemistry;

X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto (the bonding of the additional monomeric unit adjacent to the terminal monomeric unit) is at position 4 and optionally Y=Z=hydrogen;

the sugar is optionally substituted with a phenolic moiety, at any position on the sugar, for instance via an ester bond, and

pharmaceutically acceptable salts or derivatives thereof (including oxidation products).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 28 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:155675 USPATFULL

TITLE: **Methods** and compositions for regulation of 5- α -reductase activity

INVENTOR(S): Liao, Shutsung, Chicago, IL, United States

Hiipakka, Richard A., Chicago, IL, United States

PATENT ASSIGNEE(S): Arch Development Corporation, Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6576660	B1	20030610
	WO 9922728		19990514
APPLICATION INFO.:	US 2000-530443		20000428 (9)
	WO 1998-US23041		19981030

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-63770P	19971031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Owens, Amelia	
LEGAL REPRESENTATIVE:	Mayer, Brown, Rowe, & Maw, Mahoney, Joseph A., Rebman, Christine M.	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Figure(s); 10 Drawing Page(s)	
LINE COUNT:	1276	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds that inhibit 5-alpha-reductase are provided. The compounds are used to treat prostate cancer, breast cancer, obesity, skin disorders and baldness.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 29 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:113490 USPATFULL

TITLE: Orthomolecular sulpho-adenosylmethionine derivatives with antioxidant properties

INVENTOR(S): Wilburn, Michael D., Cedar Hill, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003078231	A1	20030424
APPLICATION INFO.:	US 2001-886612	A1	20010622 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR, WASHINGTON, DC, 20005		
NUMBER OF CLAIMS:	23		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	1259		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Orthomolecular Sulpho-Adenosylmethionine derivative compounds, compositions, and their uses for effecting a biological activity in an animal, such as neurochemical activity; liver biology activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compounds of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compounds of the present invention are of formula I:

##STR1##

A is 0 or N; and

X is a reaction product as defined herein.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 30 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:100191 USPATFULL

TITLE: Hydrophilic and lipophilic silibinin pro-forms

INVENTOR(S): Zielinski, Jan E., Vista, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003069302	A1	20030410
	US 6699900	B2	20040302
APPLICATION INFO.:	US 2002-110120	A1	20020405 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-282052P	20010407 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PROCOPIO, CORY, HARGREAVES & SAVITCH LLP, 530 B STREET, SUITE 2100, SAN DIEGO, CA, 92101	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	1 Drawing Page(s)	
LINE COUNT:	585	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Hydrophilic and lipophilic silibinin pro-forms and pharmaceutical compositions thereof, and **methods** of using compositions of silibinin pro-forms for topical or oral administration for treatment of disorders of cell proliferation, oxidative stress, sebaceous gland activity, and cardiovascular activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 31 OF 42 USPATFULL on STN
 ACCESSION NUMBER: 2003:59933 USPATFULL
 TITLE: Compositions of flavonoids for use as cytoprotectants and **methods** of making and using them
 INVENTOR(S): Brown, Lesley A., Cupertino, CA, United States
 Miller, Guy, Mountain View, CA, United States
 PATENT ASSIGNEE(S): Galileo Laboratories, Inc., Santa Clara, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6528042	B1	20030304
APPLICATION INFO.:	US 2000-684607		20001006 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-159003P	19991008 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Barts, Samuel	
ASSISTANT EXAMINER:	Khare, Devesh	
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3149	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-naturally-occurring compositions for use in amelioration of disruption of energy metabolism secondary to stress are described. These compositions comprise a flavonoid or derivative thereof and a synergist. Synergists include, but are not limited to, amino acids, carbohydrates, carnitines, flavonoids, nucleosides, and tocopherols and/or derivatives thereof. **Methods** of making these compositions and

methods of ameliorating disruption of energy metabolism secondary to stress, comprising administering such synergistic compositions, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 32 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2003:30869 USPATFULL
 TITLE: Formulations of tocopherols and **methods** of making and using them
 INVENTOR(S): Miller, Guy, Mountain View, CA, UNITED STATES
 Brown, Lesley A., Cupertino, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003022818	A1	20030130
APPLICATION INFO.:	US 2002-188587	A1	20020702 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-684588, filed on 6 Oct 2000, GRANTED, Pat. No. US 6426362		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-158234P	19991008 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gladys H. Monroy, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
LINE COUNT:	3092	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-naturally-occurring compositions for use in amelioration of disruption of energy metabolism secondary to stress are described. The compositions comprise a tocopherol and/or a derivative thereof, and a synergist, and are particularly suited for use as nutritional supplements. Synergists include, but are not limited to, flavonoids and lactoferrin and/or derivatives thereof. Compositions comprising an optimized formulation comprising a tocopherol and an additional compound such as daidzein or biochanin A are also described. **Methods** of making these compositions and **methods** of ameliorating injury(ies) or disruption of energy metabolism secondary to stress, comprising administering such compositions, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 33 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2002:243654 USPATFULL
 TITLE: Compositions and **methods** for the prevention and treatment of tissue ischemia
 INVENTOR(S): Miller, Guy Michael, San Jose, CA, UNITED STATES
 Brown, Lesley A., San Jose, CA, UNITED STATES
 Del Balzo, Ughetta, Morgan Hill, CA, UNITED STATES
 Flaim, Stephen, San Diego, CA, UNITED STATES
 Boddupalli, Sekhar, San Jose, CA, UNITED STATES
 Wang, Bing, Cupertino, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132845	A1	20020919
APPLICATION INFO.:	US 2001-17717	A1	20011214 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-256269P	20001215 (60)
	US 2001-296581P	20010606 (60)
	US 2001-296580P	20010606 (60)
	US 2001-343575P	20011019 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Gladys H. Monroy, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	97	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	3908	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and **methods** for the treatment of tissue ischemia, and in particular, cerebral ischemia. In particular, the present invention provides gamma-, beta-, or delta-tocopherol enriched tocopherol compositions and gamma-, beta-, or delta-tocopherol metabolite enriched compositions and/or flavonoid enriched and/or a flavonoid derivative enriched compositions and **methods** for their use in preventing or treating a tissue ischemic condition or a cerebral ischemic condition. The present invention also provides pharmaceutical compositions comprising gamma-, beta-, or delta-tocopherol enriched tocopherol composition, a gamma-, beta-, or delta-tocopherol metabolite enriched compositions or flavonoid enriched compositions or flavonoid derivative enriched compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 34 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2002:188360 USPATFULL

TITLE: Formulations of tocopherols and **methods** of making and using them

INVENTOR(S): Miller, Guy, Mountain View, CA, United States
Brown, Lesley A., Cupertino, CA, United States

PATENT ASSIGNEE(S): Galileo Laboratories, Inc., Santa Clara, CA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6426362	B1	20020730
APPLICATION INFO.:	US 2000-684588		20001006 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-158234P	19991008 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Fay, Zohreh	
ASSISTANT EXAMINER:	Kwon, Brian-Yong	
LEGAL REPRESENTATIVE:	Morrison & Foerster LLP	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	3175	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Non-naturally-occurring compositions for use in amelioration of disruption of energy metabolism secondary to stress are described. The

compositions comprise a tocopherol and/or a derivative thereof, and a synergist, and are particularly suited for use as nutritional supplements. Synergists include, but are not limited to, flavonoids and lactoferrin and/or derivatives thereof. Compositions comprising an optimized formulation comprising a tocopherol and an additional compound such as daidzein or biochanin A are also described. **Methods** of making these compositions and **methods** of ameliorating injury(ies) or disruption of energy metabolism secondary to stress, comprising administering such compositions, are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 35 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2002:181713 USPATFULL

TITLE: Cocoa extract compounds and **methods** for making and using the same

INVENTOR(S): Romanczyk, Jr., Leo J., Hackettstown, NJ, United States

PATENT ASSIGNEE(S): Mars Incorporated, McLean, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6423743	B1	20020723
APPLICATION INFO.:	US 2000-717833		20001121 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-831245, filed on 2 Apr 1997, now patented, Pat. No. US 6297273		
	Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Solola, T. A.		
LEGAL REPRESENTATIVE:	Kelley, Margaret B., Clifford Chance Rogers & Wells		
NUMBER OF CLAIMS:	18		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	246 Drawing Figure(s); 234 Drawing Page(s)		
LINE COUNT:	4656		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed and claimed are cocoa extracts, compounds, combinations thereof and compositions containing the same, such as polyphenols or procyanidins, **methods** for preparing such extracts, compounds and compositions, as well as uses for them, especially a polymeric compound of the formula A.sub.n, wherein A is a monomer of the formula: ##STR1##

wherein

n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;

R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 36 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2002:165204 USPATFULL

TITLE: Cocoa extract compounds and **methods** for making and using the same

INVENTOR(S): Romanczyk, Leo J., JR., Hackettstown, NJ, UNITED STATES

Hammerstone, John F., JR., Nazareth, PA, UNITED STATES

Buck, Margaret M., Morristown, NJ, UNITED STATES
 Post, Laurie S., Great Meadows, NJ, UNITED STATES
 Cipolla, Giovanni G., Alpha, NJ, UNITED STATES
 McClelland, Craig A., East Stroudsburg, PA, UNITED STATES
 Mundt, Jeff A., Hackettstown, NJ, UNITED STATES
 Schmitz, Harold H., Branchburg, NJ, UNITED STATES
 Mars, Incorporated (U.S. corporation)

PATENT ASSIGNEE(S):

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002086833	A1	20020704
	US 6638971	B2	20031028
APPLICATION INFO.:	US 2001-776649	A1	20010205 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1997-831245, filed on 2 Apr 1997, GRANTED, Pat. No. US 6297273 Continuation-in-part of Ser. No. US 1996-631661, filed on 2 Apr 1996, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Clifford Chance Rogers & Wells LLP, 200 Park Avenue, New York, NY, 10166-0153		
NUMBER OF CLAIMS:	208		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	240 Drawing Page(s)		
LINE COUNT:	5797		
CAS INDEXING IS AVAILABLE FOR THIS PATENT.			
AB	Polyphenol-containing compositions, for example cocoa procyanidin monomer and/or oligomer-containing compositions, and their use for inhibiting bacterial growth are disclosed. Compositions may be used for human and veterinary animal administration and may be, for example, in a form of a food, a dietary supplement, or a pharmaceutical.		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 37 OF 42 USPATFULL on STN
 ACCESSION NUMBER: 2001:182576 USPATFULL
 TITLE: Flavonoide esters and their use notably in cosmetics
 INVENTOR(S): Perrier, Eric, Les Cotes D'Arey, France
 Mariotte, Anne-Marie, St.Simeon De Bressieux, France
 Boumendjel, Ahcene, La Tronche, France
 Bresson-Rival, Delphine, Lyon, France
 PATENT ASSIGNEE(S): COLETICA, Lyon, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2001031735	A1	20011018
	US 6471973	B2	20021029
APPLICATION INFO.:	US 2001-828986	A1	20010410 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-113158, filed on 10 Jul 1998, GRANTED, Pat. No. US 6235294		

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-6194	19980515
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ARMSTRONG, WESTERMAN, HATTORI,, MCLELAND & NAUGHTON, LLP, 1725 K STREET, NW, SUITE 1000, WASHINGTON, DC, 20006	

NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 1217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to a flavonoid ester.

This flavonoid ester results from the reaction product of at least one flavonoid selected from the group consisting of a flavonoid with a ketone group in the 4-position, a salt, ester or ether of such a flavonoid, and a C-heteroside and/or O-heteroside derivative of such a flavonoid, with the proviso that this flavonoid contains at least one free alcohol group, with an organic monoacid having from 3 to 30 carbon atoms.

These flavonoid esters constitute useful active principles for the manufacture of cosmetic, dermopharmaceutical, pharmaceutical, dietetic or agri-foodstuff compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 38 OF 42 USPATFULL on STN
ACCESSION NUMBER: 2001:168156 USPATFULL
TITLE: Use of cocoa solids having high cocoa polyphenol content in tableting compositions and capsule filling compositions
INVENTOR(S): Romanczyk, Jr., Leo J., Hackettstown, NJ, United States
PATENT ASSIGNEE(S): Mars, Inc., McLean, VA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6297273	B1	20011002
APPLICATION INFO.:	US 1997-831245		19970402 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Tsang, Cecilia		
ASSISTANT EXAMINER:	Solola, Taofiq A.		
LEGAL REPRESENTATIVE:	Kelley, Margaret B.	Clifford Chance Rogers & Wells, LLP	
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	237 Drawing Figure(s); 221 Drawing Page(s)		
LINE COUNT:	4861		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed and claimed are cocoa extracts, compounds, combinations thereof and compositions containing the same, such as polyphenols or procyanidins, **methods** for preparing such extracts, compounds and compositions, as well as uses for them, especially a polymeric compound of the formula A.sub.n, wherein A is a monomer of the formula: ##STR1##

wherein n is an integer from 2 to 18, such that there is at least one terminal monomeric unit A, and one or a plurality of additional monomeric units;

R is 3-(α)-OH, 3-(β)-OH, 3-(α)-O-sugar, or 3-(β)-O-sugar;

bonding between adjacent monomers takes place at positions 4, 6 or 8;

a bond of an additional monomeric unit in position 4 has alpha or beta

stereochemistry;

X, Y and Z are selected from the group consisting of monomeric unit A, hydrogen, and a sugar, with the provisos that as to the at least one terminal monomeric unit, bonding of the additional monomeric unit thereto (the bonding of the additional monomeric unit adjacent to the terminal monomeric unit) is at position 4 and optionally Y=Z=hydrogen;

the sugar is optionally substituted with a phenolic moiety, at any position on the sugar, for instance via an ester bond, and

pharmaceutically acceptable salts or derivatives thereof (including oxidation products).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 39 OF 42 USPATFULL on STN

ACCESSION NUMBER: 2001:74947 USPATFULL
 TITLE: Flavonoide esters and their use notably in cosmetics
 INVENTOR(S): Perrier, Eric, Les Cotes D'Arey, France
 Mariotte, Anne-Marie, St. Simeon De Bressieux, France
 Boumendjel, Ahcene, La Tronche, France
 Bresson-Rival, Delphine, Lyons, France
 PATENT ASSIGNEE(S): Coletica, Lyons, France (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6235294	B1	20010522
APPLICATION INFO.:	US 1998-113158		19980710 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	FR 1998-6194	19980515
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Page, Thurman K.	
ASSISTANT EXAMINER:	Channavajjaia, Lakshmi	
LEGAL REPRESENTATIVE:	Armstrong, Westerman, Hattori, McLeland & Naughton, LLP	
NUMBER OF CLAIMS: -	12	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1022	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to a flavonoid ester. This flavonoid ester results from the reaction product of at least one flavonoid selected from the group consisting of a flavonoid with a ketone group in the 4-position, a salt, ester or ether of such a flavonoid, and a C-heteroside and/or O-heteroside derivative of such a flavonoid, with the proviso that this flavonoid contains at least one free alcohol group, with an organic monoacid having from 3 to 30 carbon atoms. These flavonoid esters constitute useful active principles for the manufacture of cosmetic, dermopharmaceutical, pharmaceutical, dietetic or agri-foodstuff compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 40 OF 42 USPATFULL on STN

ACCESSION NUMBER: 1998:108428 USPATFULL
 TITLE: Agent for the prevention or treatment of cataracts
 INVENTOR(S): Yamakoshi, Jun, Chiba, Japan
 Ariga, Toshiaki, Chiba, Japan

Ishikawa, Hiroharu, Chiba, Japan
 Iwai, Yukihiro, Chiba, Japan
 Manaka, Tatuo, Chiba, Japan
 Kataoka, Shigehiro, Chiba, Japan
 Yuasa, Katsumi, Chiba, Japan
 Kikuchi, Mamoru, Chiba, Japan
 PATENT ASSIGNEE(S): Kikkoman Corporation, Noda, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5804597		19980908
APPLICATION INFO.:	US 1997-779097		19970106 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1996-168664	19960610
	JP 1996-307514	19961105
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Fay, Zohreh	
LEGAL REPRESENTATIVE:	Pennie & Edmonds LLP	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Figure(s); 3 Drawing Page(s)	
LINE COUNT:	593	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB An agent for the prevention or treatment of cataracts comprising a proanthocyanidin oligomer is provided. The oral administration or application to the eyes of the agent of the invention produces a sufficient preventive or therapeutic effect against cataracts caused by oxidative disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 41 OF 42 USPATFULL on STN
 ACCESSION NUMBER: 97:64032 USPATFULL
 TITLE: Chondroprotective agents
 INVENTOR(S): Watanabe, Koju, Saitama, Japan
 Niimura, Koichi, Saitama, Japan
 Umekawa, Kiyonori, Chiba, Japan
 PATENT ASSIGNEE(S): Kureha Chemical Industry Co., Ltd., Tokyo, Japan (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5650433		19970722
APPLICATION INFO.:	US 1995-519179		19950825 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-271951, filed on 8 Jul 1994, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	JP 1993-194182	19930709
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Sughrue, Mion, Zinn, Macpeak & Seas	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	

LINE COUNT: 478

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A chondroprotective agent comprising a flavonoid compound of the general formula (I): ##STR1## wherein R.sup.1 to R.sup.9 are, independently, a hydrogen atom, hydroxyl group, or methoxyl group and X is a single bond or a double bond, or a stereoisomer thereof, or a naturally occurring glycoside thereof is disclosed. The above compound strongly inhibits proteoglycan depletion from the chondrocyte matrix and exhibits a function to protect cartilage, and thus, is extremely effective for the treatment of arthropathy.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L43 ANSWER 42 OF 42 USPATFULL on STN

ACCESSION NUMBER: 86:57928 USPATFULL

TITLE: Flavonoid phosphate salts of aminoglycoside antibiotics

INVENTOR(S): Wahlig, Helmut, Darmstadt, Germany, Federal Republic of
Dingeldein, Elvira, Dreieich, Germany, Federal Republic ofPATENT ASSIGNEE(S): Kirchlechner, Richard, Rott a. Inn, Germany, Federal Republic of
Orth, Dieter, Darmstadt, Germany, Federal Republic of
Rogalski, Werner, Alsbach, Germany, Federal Republic of
Merck Patent Gesellschaft mit beschraenkter Haftung, Darmstadt, Germany, Federal Republic of (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4617293		19861014
APPLICATION INFO.:	US 1984-613131		19840523 (6)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1982-377779, filed on 13 May 1982, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	DE 1981-3118856	19810513
	DE 1982-3206725	19820225
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Brown, Johnnie R.	
ASSISTANT EXAMINER:	Peselev, Elli	
LEGAL REPRESENTATIVE:	Millen & White	
NUMBER OF CLAIMS:	12	
EXEMPLARY CLAIM:	1,11	
LINE COUNT:	528	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Flavonoid phosphates of aminoglycoside antibiotics are useful sparingly soluble salts, e.g., for achieving a depot effect.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.